{"id": "4541abfb-90c1-4479-ac53-9128f0cbb3de", "page": 1, "type": "paragraph", "text": "The new engl and jour nal of medicine"}
{"id": "0712feb1-3e61-4db3-96f7-04235a8472fb", "page": 1, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "4993f39f-4556-4bb6-8b76-e7cee17d113e", "page": 1, "type": "paragraph", "text": "2245"}
{"id": "fd0ecfe3-50f7-46a0-b97e-155f7f6ea2be", "page": 1, "type": "paragraph", "text": "From the Kaiser Permanente Vaccine"}
{"id": "98fd49e5-9201-441e-badc-7775ad9645fc", "page": 1, "type": "paragraph", "text": "Study Center, Oakland, CA. Dr. Klein can"}
{"id": "4290c82f-73c9-4c65-945a-ae8ab46a244f", "page": 1, "type": "paragraph", "text": "be contacted at nicola.klein@kp.org or at"}
{"id": "7c09091f-ee11-44de-8f0a-895756ff10a1", "page": 1, "type": "paragraph", "text": "the Kaiser Permanente Vaccine Study"}
{"id": "f876fc2d-2c82-481d-b0e3-2da20329ce7f", "page": 1, "type": "paragraph", "text": "Center, 1 Kaiser Plaza, 17th Fl., Oakland,"}
{"id": "a02e614f-26b3-45ad-aa2c-231fb0c9e5d7", "page": 1, "type": "paragraph", "text": "CA 94612."}
{"id": "26901217-fda3-4aec-86b4-bdb7c4c72d74", "page": 1, "type": "paragraph", "text": "N Engl J Med 2023;389:2245-55."}
{"id": "5006737d-4a66-4f75-8e2f-5f4d073db032", "page": 1, "type": "paragraph", "text": "DOI: 10.1056/NEJMoa2302099"}
{"id": "b8dff86f-8285-479c-92be-4f3217c075e3", "page": 1, "type": "paragraph", "text": "Copyright \u00a9 2023 Massachusetts Medical Society."}
{"id": "89951ec4-4cf4-43e2-aa7d-cbc54eceaa92", "page": 1, "type": "paragraph", "text": "BACKGROUND"}
{"id": "03b44489-62f6-4835-be55-9f2c2a20b190", "page": 1, "type": "paragraph", "text": "Quadrivalent recombinant influenza vaccines contain three times the amount of"}
{"id": "06bd0462-d7b9-4ed4-83a4-87a7804c0bc0", "page": 1, "type": "paragraph", "text": "hemagglutinin protein as standard-dose egg-based vaccines, and the recombinant"}
{"id": "1d5cd40e-1ef4-4629-a5be-255e76a0301b", "page": 1, "type": "paragraph", "text": "formulation is not susceptible to antigenic drift during manufacturing. Data are"}
{"id": "44491734-df21-41ad-a4e0-4ef8bee1db98", "page": 1, "type": "paragraph", "text": "needed on the relative effectiveness of recombinant vaccines as compared with"}
{"id": "7b156529-8235-47c1-b829-6b768872b8f2", "page": 1, "type": "paragraph", "text": "standard-dose vaccines against influenza-related outcomes in adults under the age"}
{"id": "af9c9545-c60e-46d0-9e3c-34130aef67ef", "page": 1, "type": "paragraph", "text": "of 65 years."}
{"id": "1019d7ca-5083-4ffd-94ec-3c3e0919a772", "page": 1, "type": "paragraph", "text": "METHODS"}
{"id": "488a3693-5f83-4e5d-a6ea-1c29f18e7808", "page": 1, "type": "paragraph", "text": "In this cluster-randomized observational study, Kaiser Permanente Northern Cali-"}
{"id": "b20531be-831d-4b0d-a03c-996d85c217fc", "page": 1, "type": "paragraph", "text": "fornia facilities routinely administered either a high-dose recombinant influenza"}
{"id": "0e3d361e-d863-420b-9f99-7d04c9b51ef7", "page": 1, "type": "paragraph", "text": "vaccine (Flublok Quadrivalent) or one of two standard-dose influenza vaccines"}
{"id": "4b8f5404-714a-459b-a14f-167c70419477", "page": 1, "type": "paragraph", "text": "during the 2018\u20132019 and 2019\u20132020 influenza seasons to adults 50 to 64 years"}
{"id": "02e9e94c-adbe-43b7-af94-16034b85a4e6", "page": 1, "type": "paragraph", "text": "of age (primary age group) and 18 to 49 years of age. Each facility alternated"}
{"id": "701f0f9b-b231-4f22-a4d6-a490511d278f", "page": 1, "type": "paragraph", "text": "weekly between the two vaccine formulations. The primary outcome was influ-"}
{"id": "e9b56256-dcc5-49d7-b832-deedef53ca3c", "page": 1, "type": "paragraph", "text": "enza (A or B) confirmed by polymerase-chain-reaction (PCR) testing. Secondary"}
{"id": "52184dac-d0a2-4cd3-8840-cafc864d27c0", "page": 1, "type": "paragraph", "text": "outcomes included influenza A, influenza B, and influenza-related hospitalization"}
{"id": "e21ec35b-0838-4bc5-9917-fe473bd73f18", "page": 1, "type": "paragraph", "text": "outcomes. We used Cox regression analysis to estimate the hazard ratio of the"}
{"id": "62486a4c-ec71-45fd-bdcc-c65922f5e295", "page": 1, "type": "paragraph", "text": "recombinant vaccine as compared with the standard-dose vaccines against each"}
{"id": "7bdfbeb9-8c72-4a5c-9ad4-6a026684e1c2", "page": 1, "type": "paragraph", "text": "outcome. We calculated the relative vaccine effectiveness as 1 minus the hazard"}
{"id": "8b8b20f3-77b9-4eba-af95-9e937284641a", "page": 1, "type": "paragraph", "text": "ratio."}
{"id": "832e1fc7-5f4b-4bfd-8da8-d39d803ff067", "page": 1, "type": "paragraph", "text": "RESULTS"}
{"id": "01a53673-9cec-43b7-ae25-8dc3e1818b90", "page": 1, "type": "paragraph", "text": "The study population included 1,630,328 vaccinees between the ages of 18 and 64"}
{"id": "8fc904e1-666b-4b9a-894e-a9a87f9ce79f", "page": 1, "type": "paragraph", "text": "years (632,962 in the recombinant-vaccine group and 997,366 in the standard-dose"}
{"id": "392fedc5-b9e6-4b1c-b871-ef023e008fe1", "page": 1, "type": "paragraph", "text": "group). During this study period, 1386 cases of PCR-confirmed influenza were"}
{"id": "2137b609-6153-42cb-beab-56850d3e9af2", "page": 1, "type": "paragraph", "text": "diagnosed in the recombinant-vaccine group and 2435 cases in the standard-dose"}
{"id": "26252304-b4c5-4e3d-966a-4b072f370c2d", "page": 1, "type": "paragraph", "text": "group. Among the participants who were 50 to 64 years of age, 559 participants"}
{"id": "7c80c030-4643-4c74-9436-b900da2e688a", "page": 1, "type": "paragraph", "text": "(2.00 cases per 1000) tested positive for influenza in the recombinant-vaccine"}
{"id": "f9cbbabd-c0e0-418c-a9b9-e9673278edf9", "page": 1, "type": "paragraph", "text": "group as compared with 925 participants (2.34 cases per 1000) in the standard-"}
{"id": "4439e832-9f8d-4e52-aaed-f6025b86ad77", "page": 1, "type": "paragraph", "text": "dose group (relative vaccine effectiveness, 15.3%; 95% confidence interval [CI], 5.9"}
{"id": "185db66f-69cc-4773-8d69-d58dac235291", "page": 1, "type": "paragraph", "text": "to 23.8; P = 0.002). In the same age group, the relative vaccine effectiveness against"}
{"id": "297507ea-1ba9-49cd-81f0-a32491363951", "page": 1, "type": "paragraph", "text": "influenza A was 15.7% (95% CI, 6.0 to 24.5; P = 0.002). The recombinant vaccine"}
{"id": "f63ddf51-af1b-4330-b109-2e8b2cd337bf", "page": 1, "type": "paragraph", "text": "was not significantly more protective against influenza-related hospitalization"}
{"id": "b0130437-17c2-49d7-acbc-d6f0e5d3f735", "page": 1, "type": "paragraph", "text": "than were the standard-dose vaccines."}
{"id": "32f218da-127a-4a95-a7b1-03e51eefb4ec", "page": 1, "type": "paragraph", "text": "CONCLUSIONS"}
{"id": "a05beae2-bce2-4368-9c6d-00018842301f", "page": 1, "type": "paragraph", "text": "The high-dose recombinant vaccine conferred more protection against PCR-con-"}
{"id": "be67028e-28ff-4f9f-92ab-ad538de4850a", "page": 1, "type": "paragraph", "text": "firmed influenza than an egg-based standard-dose vaccine among adults between"}
{"id": "b493fd48-7a94-46b8-baf7-3b5183585e67", "page": 1, "type": "paragraph", "text": "the ages of 50 and 64 years. (Funded by Sanofi; ClinicalTrials.gov number,"}
{"id": "ae178f1d-d443-407a-8607-5aae6feecfc4", "page": 1, "type": "paragraph", "text": "NCT03694392.)"}
{"id": "838f3e76-acb1-4ae7-8009-c9349be5a16b", "page": 1, "type": "paragraph", "text": "ABSTR ACT"}
{"id": "9ff2c0b3-39d2-4cc1-82e3-040b13adef97", "page": 1, "type": "paragraph", "text": "Recombinant or Standard-Dose Influenza"}
{"id": "7d7289ec-d6cb-4d03-8aa2-a65cf40ecbc4", "page": 1, "type": "paragraph", "text": "Vaccine in Adults under 65 Years of Age"}
{"id": "0e644b8d-ed85-44c6-b8cf-538282c9f074", "page": 1, "type": "paragraph", "text": "Amber Hsiao, Ph.D., M.P.H., Arnold Yee, M.B.A., Bruce Fireman, M.A.,"}
{"id": "9c6db949-d43e-4d52-9e49-fe202dd7694f", "page": 1, "type": "paragraph", "text": "John Hansen, M.P.H., Ned Lewis, M.P.H., and Nicola P. Klein, M.D., Ph.D.\u200b"}
{"id": "dd43f7f3-6300-4504-9669-8ce5bbcb0b3a", "page": 1, "type": "paragraph", "text": "Original Article"}
{"id": "1acc0ed8-69c8-4fa0-8171-31d5c3304e1d", "page": 1, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "1c3a0e6d-c118-483f-a794-fef97023f788", "page": 1, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "9b9fe76c-062c-4197-b945-9589984d342e", "page": 1, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "8aa49e9f-16fc-4bab-a595-ba88dd2b121b", "page": 2, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "67ede384-e476-4c35-a592-43725317628f", "page": 2, "type": "paragraph", "text": "2246"}
{"id": "bedf20a3-f3e0-46c9-b2a2-12446a354a63", "page": 2, "type": "paragraph", "text": "The new engl and jour nal of medicine"}
{"id": "0e149fd8-d380-49c8-a2ff-1c244b88942f", "page": 2, "type": "paragraph", "text": "E"}
{"id": "a19942fd-0e3b-4721-9c16-6cfcfa17bdcf", "page": 2, "type": "paragraph", "text": "very year in the United States, in-"}
{"id": "adfd1643-80d8-4d65-9051-c7f01f3d033b", "page": 2, "type": "paragraph", "text": "fluenza causes mild-to-severe illness in a"}
{"id": "103a0531-ba8f-4a73-9b9d-9e4f1d41c666", "page": 2, "type": "paragraph", "text": "wide range of persons (9 million to 41"}
{"id": "94741b0c-2f35-4b86-9b2e-21590421183f", "page": 2, "type": "paragraph", "text": "million).1 Influenza vaccination is the primary"}
{"id": "8ec26fe5-a7cf-467f-ad59-19ee86ff9c42", "page": 2, "type": "paragraph", "text": "method for preventing influenza-related illness-"}
{"id": "9bfd64ea-5ed2-403c-bd17-ba388e35da06", "page": 2, "type": "paragraph", "text": "es,2 although the vaccine effectiveness ranges"}
{"id": "094cf78d-fa47-4039-854e-a160fecbb548", "page": 2, "type": "paragraph", "text": "from 20% in years in which the vaccine is anti-"}
{"id": "ab87056e-77ed-4d6c-b26d-147dfbff1490", "page": 2, "type": "paragraph", "text": "genically mismatched to the circulating viral"}
{"id": "18d58b4c-8a22-4bd6-b4aa-c2aa5c126d24", "page": 2, "type": "paragraph", "text": "strain to 40 to 60% in years in which the vaccine"}
{"id": "689db3b0-7d11-449b-a0eb-4046dcf46195", "page": 2, "type": "paragraph", "text": "is antigenically well matched.2,3 This large varia-"}
{"id": "8ccc9ee2-09cb-4a63-b93f-f5b691d42326", "page": 2, "type": "paragraph", "text": "tion in effectiveness between years suggests that"}
{"id": "c42590d3-68f4-4d0a-9a52-d129f1c099f5", "page": 2, "type": "paragraph", "text": "more effective vaccines are needed."}
{"id": "99e10ed1-3575-4b92-99ac-db4983502d5b", "page": 2, "type": "paragraph", "text": "In traditional quadrivalent standard-dose in-"}
{"id": "fb9cb827-26b4-477d-b83f-1afc7c86db4e", "page": 2, "type": "paragraph", "text": "activated influenza vaccines (SD-IIV4), chicken"}
{"id": "13cac887-960d-49ef-9c27-d6b206bed740", "page": 2, "type": "paragraph", "text": "eggs are used to manufacture the influenza"}
{"id": "740dd908-0e54-40a7-b1c5-05655705f3d3", "page": 2, "type": "paragraph", "text": "virus. Mutations in the hemagglutinin protein"}
{"id": "1426efec-cc57-4685-a41c-8091379c34b4", "page": 2, "type": "paragraph", "text": "during egg-based manufacturing can result in"}
{"id": "2b2f3ec6-e31b-421c-85d9-d607a17f5259", "page": 2, "type": "paragraph", "text": "mismatch between the selected strain and the"}
{"id": "2637bb63-833e-41a5-a424-aa022668c200", "page": 2, "type": "paragraph", "text": "vaccine strain.4 The Flublok Quadrivalent influ-"}
{"id": "5f6cd74d-dbab-404f-b026-bfd331231544", "page": 2, "type": "paragraph", "text": "enza vaccine (RIV4, Sanofi) is manufactured"}
{"id": "b589d954-0b4c-45fe-ba1f-3b901eb0ba2a", "page": 2, "type": "paragraph", "text": "without chicken eggs, resulting in a recombinant"}
{"id": "5886281d-6a6d-4017-92a8-a8565530b3e7", "page": 2, "type": "paragraph", "text": "hemagglutinin protein that is genetically identi-"}
{"id": "53287dc7-2aa9-453f-adc3-874659a110de", "page": 2, "type": "paragraph", "text": "cal to that in the selected strain.5 The vaccine"}
{"id": "6b4d6975-ef1c-49bd-9203-8df7a059aa56", "page": 2, "type": "paragraph", "text": "also contains three times the amount of hemag-"}
{"id": "0e875483-2022-4606-ab6b-d93f576e5769", "page": 2, "type": "paragraph", "text": "glutinin protein as standard-dose vaccines, an"}
{"id": "86cef933-65e6-4c36-bc29-2ff2fc460766", "page": 2, "type": "paragraph", "text": "increased level that has been correlated with"}
{"id": "c5b33205-2a94-4c94-95ac-a14fb42e65f8", "page": 2, "type": "paragraph", "text": "increased protective hemagglutinin antibodies.6"}
{"id": "be13352d-0d20-4410-a4fa-745e2380f77b", "page": 2, "type": "paragraph", "text": "To estimate the relative effectiveness of the"}
{"id": "cfdb4a9b-9d4a-4b58-9afa-6c1c3621e44e", "page": 2, "type": "paragraph", "text": "recombinant vaccine as compared with standard-"}
{"id": "69493392-314c-4e68-b820-8d46186cee38", "page": 2, "type": "paragraph", "text": "dose vaccines against laboratory-confirmed in-"}
{"id": "562dac8f-f342-475e-9378-997c8e23e1cf", "page": 2, "type": "paragraph", "text": "fluenza and influenza-related outcomes, we com-"}
{"id": "92c1e8fa-3479-43f6-ac43-d2633b434898", "page": 2, "type": "paragraph", "text": "pared the two formulations of vaccines among"}
{"id": "12b6a46a-b488-46f9-b765-81c993df0401", "page": 2, "type": "paragraph", "text": "members of the Kaiser Permanente Northern"}
{"id": "c03c0453-fb1f-4d4b-b871-0c4b5640acfb", "page": 2, "type": "paragraph", "text": "California (KPNC) health care system who were"}
{"id": "4ae7e1e8-31a9-4461-a596-684b94fac3d0", "page": 2, "type": "paragraph", "text": "between 18 and 64 years of age during the two"}
{"id": "dfd58fff-dcc2-4955-8dc8-c6a330750edc", "page": 2, "type": "paragraph", "text": "influenza seasons of 2018\u20132019 and 2019\u20132020."}
{"id": "7f2bd186-5eea-48cb-a5ac-2a6351ceae6f", "page": 2, "type": "paragraph", "text": "Methods"}
{"id": "c40b2491-1c32-458a-98b6-7ee77257fd40", "page": 2, "type": "paragraph", "text": "Study Population and Oversight"}
{"id": "c6837f6b-caf1-4ee2-9e39-d4165d31de87", "page": 2, "type": "paragraph", "text": "KPNC is an integrated health care delivery sys-"}
{"id": "dd6a045e-8a12-471d-97d3-f47d38ec65bf", "page": 2, "type": "paragraph", "text": "tem with 4.6 million members, nearly 65% of"}
{"id": "005a17f8-d5ed-4aac-9067-575e8f4c294e", "page": 2, "type": "paragraph", "text": "whom are adults between the ages of 18 and 64"}
{"id": "f4a7fbf9-1275-45e7-a2b8-6305582192c8", "page": 2, "type": "paragraph", "text": "years. Members receive nearly all their care at"}
{"id": "45c4a52b-92cc-4113-80bb-6629b1d7fa10", "page": 2, "type": "paragraph", "text": "system-owned facilities, which includes 259"}
{"id": "e28a7b1b-2a7f-433e-8e9e-e14bafad1530", "page": 2, "type": "paragraph", "text": "medical clinics and 21 hospitals. The members\u2019"}
{"id": "c28b531d-630b-4715-883a-9b1008f77d9f", "page": 2, "type": "paragraph", "text": "electronic medical records capture all medical"}
{"id": "9f5b6375-9a05-4699-a38f-1a0474863ac2", "page": 2, "type": "paragraph", "text": "services, including inpatient and outpatient di-"}
{"id": "62811769-4538-46f0-a55d-b29321da1458", "page": 2, "type": "paragraph", "text": "agnoses, laboratory tests, and vaccinations. The"}
{"id": "1acf9c39-0c4d-43a3-b0cb-cea9a9c1c5ed", "page": 2, "type": "paragraph", "text": "KPNC members include approximately a third"}
{"id": "0a6febcc-3a98-4d40-ae22-2270cd0bafcd", "page": 2, "type": "paragraph", "text": "of the population in Northern California and"}
{"id": "9a43a41f-7945-43b5-bdf4-f2bfabfd09b2", "page": 2, "type": "paragraph", "text": "broadly represent adults in California regarding"}
{"id": "ad0af560-fa6b-4607-bad1-769c64835af8", "page": 2, "type": "paragraph", "text": "racial, ethnic, and socioeconomic characteristics,"}
{"id": "ce89e4a0-34da-44d9-9a16-f9774593e34f", "page": 2, "type": "paragraph", "text": "although the proportions of Hispanic, Asian,"}
{"id": "2b70e56c-57f4-473b-9129-d6df5769f429", "page": 2, "type": "paragraph", "text": "and multiracial residents are higher than those"}
{"id": "ea3d895c-25d6-4dbb-a93b-d3e6282099de", "page": 2, "type": "paragraph", "text": "in other U.S. regions (Table S1 in the Supple-"}
{"id": "07fb6adb-6978-424c-aa80-cd2f18fc4cec", "page": 2, "type": "paragraph", "text": "mentary Appendix, available with the full text of"}
{"id": "aa85e9b0-226a-4876-9f20-e7f3eb5e4c99", "page": 2, "type": "paragraph", "text": "this article at NEJM.org).7 Approximately 10%"}
{"id": "cb2083f3-b1bd-4e98-9d61-1c45262001c6", "page": 2, "type": "paragraph", "text": "of the members are covered by Medicaid.8 The"}
{"id": "67342c7a-4f63-48d8-adde-6920b4eecaf0", "page": 2, "type": "paragraph", "text": "KPNC institutional review board approved the"}
{"id": "6e06a222-58e3-43bd-a930-f5003f7ee9f3", "page": 2, "type": "paragraph", "text": "study with a waiver of informed consent."}
{"id": "1a022e30-d5e3-426d-b915-4f8b454e5184", "page": 2, "type": "paragraph", "text": "Representatives of the study sponsor, Sanofi,"}
{"id": "2c4ad304-f49c-4a1c-868c-49c75ab4523e", "page": 2, "type": "paragraph", "text": "did not have a role in the design or conduct of"}
{"id": "eea9f9c1-9fc2-4471-8ec7-e33fd505c0ac", "page": 2, "type": "paragraph", "text": "the study or in the analyses of the data. The"}
{"id": "12ae5232-d626-486a-a28c-b1d4a2060122", "page": 2, "type": "paragraph", "text": "Flublok Quadrivalent influenza vaccine was"}
{"id": "4fb10ad7-8fe9-4d22-8614-f9f437d3e960", "page": 2, "type": "paragraph", "text": "donated by Sanofi, and the two standard-dose"}
{"id": "4033741c-3fbd-4602-b89c-9fa7d43a4c67", "page": 2, "type": "paragraph", "text": "vaccines used during the study seasons were"}
{"id": "b8d02eb1-13e9-490f-a27f-a7e9f724d1b2", "page": 2, "type": "paragraph", "text": "purchased by KPNC. The first author wrote the"}
{"id": "bb7f73b8-ffa7-4229-b94e-0ad9bdc23468", "page": 2, "type": "paragraph", "text": "first draft of the manuscript. The authors vouch"}
{"id": "9090ab60-e3dd-42b1-925c-9ed05c7f2861", "page": 2, "type": "paragraph", "text": "for the accuracy and completeness of the data"}
{"id": "b510309e-22de-41ef-8bc7-c7e8a89650ff", "page": 2, "type": "paragraph", "text": "presented and for the fidelity of the study to the"}
{"id": "8ec6c09e-eb39-4b16-a071-1f56af23c0d8", "page": 2, "type": "paragraph", "text": "protocol (available at NEJM.org)."}
{"id": "c3de53ba-692b-4b46-9a7d-e4f4cccfae65", "page": 2, "type": "paragraph", "text": "Study Design"}
{"id": "0ba88d06-0da2-4c8c-be60-d84f0b699628", "page": 2, "type": "paragraph", "text": "This was a cluster-randomized observational"}
{"id": "9b37f897-10f5-47c6-ad2a-770df1269ee9", "page": 2, "type": "paragraph", "text": "study that was designed to include all KPNC"}
{"id": "37e4e845-c4de-4348-ab77-7209edee67e0", "page": 2, "type": "paragraph", "text": "members between the ages of 18 and 64 years"}
{"id": "4da68a7b-4a7f-4f65-bcc0-3976f8139184", "page": 2, "type": "paragraph", "text": "who had received a licensed recombinant or"}
{"id": "4665034a-d3fe-4dc0-9f48-1dfea4157248", "page": 2, "type": "paragraph", "text": "standard-dose vaccine as part of routine clinical"}
{"id": "602d400f-6c11-469c-9dc3-f079fdc34e7d", "page": 2, "type": "paragraph", "text": "care during the three influenza seasons from"}
{"id": "c171b61e-ce7b-4700-a19c-92c0de3e14ab", "page": 2, "type": "paragraph", "text": "2018 to 2021.9 The 2019\u20132020 season was trun-"}
{"id": "8c853837-59f0-4e40-b4d3-edcd1660aab4", "page": 2, "type": "paragraph", "text": "cated in March 2020 because of the outbreak of"}
{"id": "b2797412-18f3-4819-9140-da6f3648aa6e", "page": 2, "type": "paragraph", "text": "the coronavirus disease 2019 pandemic; data"}
{"id": "ba8a3186-9623-430d-ae1c-7f4c29ac434f", "page": 2, "type": "paragraph", "text": "from the 2020\u20132021 season were subsequently"}
{"id": "225f8162-cead-4932-aa5c-4a1f49df204e", "page": 2, "type": "paragraph", "text": "excluded from the analyses because there were"}
{"id": "2ccb18fa-060a-483a-951c-cc34bf783cb0", "page": 2, "type": "paragraph", "text": "too few cases of influenza during the pandemic"}
{"id": "1d8ffd20-32bb-435a-be69-8413d4d854b8", "page": 2, "type": "paragraph", "text": "to be informative. During the study period, influ-"}
{"id": "48256806-32db-46f7-95d9-1b1f765992e0", "page": 2, "type": "paragraph", "text": "enza vaccination coverage was similar to national"}
{"id": "9e8bf3d4-50c9-4732-86bf-14bce7413b47", "page": 2, "type": "paragraph", "text": "coverage (Table S1). The study excluded unvac-"}
{"id": "a41b06f0-eb2a-48d9-b9fe-a9b87cca51bd", "page": 2, "type": "paragraph", "text": "cinated patients."}
{"id": "832e6f75-64f8-4354-87d7-c4c729bf3109", "page": 2, "type": "paragraph", "text": "The KPNC system includes seven geographic"}
{"id": "75dcf6c8-78ab-432c-a9cf-67b680489aad", "page": 2, "type": "paragraph", "text": "regions, each containing 8 to 12 medical facili-"}
{"id": "98483ad6-797d-4007-a5c1-fa4aac7ff241", "page": 2, "type": "paragraph", "text": "ties. In each region, the facilities were assigned"}
{"id": "e3bfa37a-f89f-4e95-a1b6-95ed0f6ce656", "page": 2, "type": "paragraph", "text": "to either Block A or Block B to optimize the bal-"}
{"id": "ba6f2780-3ec9-48ce-9dbc-391b5590e29a", "page": 2, "type": "paragraph", "text": "ance between blocks with respect to facility size"}
{"id": "e6a70184-5acc-45a9-95c3-6aad03c5721e", "page": 2, "type": "paragraph", "text": "(Fig. 1). We randomly assigned Block A to start"}
{"id": "3fa6bc66-8827-4c0a-9f96-a6181037b3e1", "page": 2, "type": "paragraph", "text": "with administration of a standard-dose vaccine"}
{"id": "eb866d71-5dc6-49ab-8c74-a8d97765ada3", "page": 2, "type": "paragraph", "text": "and Block B to start with administration of the"}
{"id": "c8238c94-7359-42ec-8812-b6211b884d07", "page": 2, "type": "paragraph", "text": "recombinant vaccine. Thereafter, each facility"}
{"id": "9c2d98c3-89f1-48ad-a47f-d6fc7494aa5a", "page": 2, "type": "paragraph", "text": "alternated the administration of the two vac-"}
{"id": "bc759716-ba2e-4361-b890-5a8acaedf9f9", "page": 2, "type": "paragraph", "text": "cines weekly."}
{"id": "8bff9d10-6d9c-4b36-aa8d-4d1a43e8791c", "page": 2, "type": "paragraph", "text": "Key features of the study design were that"}
{"id": "3a3707ee-c2f7-4ff9-9d61-c40d2480fd25", "page": 2, "type": "paragraph", "text": "A Quick Take"}
{"id": "66f02ce1-420c-4cf8-a68f-55644529fd4d", "page": 2, "type": "paragraph", "text": "is available at"}
{"id": "a4b42de5-c83d-4351-b96b-d20cdf3737f0", "page": 2, "type": "paragraph", "text": "NEJM.org"}
{"id": "db641e16-2629-49d6-aa2f-bff4926fd29f", "page": 2, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "063dc001-f7f1-48c4-8c66-eb6b109c7c82", "page": 2, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "24c6b9d9-81a8-4db4-8074-9f058f027fef", "page": 2, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "bdf5a96c-4aa2-40aa-a9de-6d833ec3278b", "page": 3, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "5a4f0f92-c7d5-4cb6-9f56-d9f8690daf3f", "page": 3, "type": "paragraph", "text": "2247"}
{"id": "99a6479c-30a9-4dd5-9692-4e3ce6d71d3c", "page": 3, "type": "paragraph", "text": "Recombinant or Standard-Dose Influenza Vaccine"}
{"id": "ccc277a9-3d9c-4428-8cf9-87081d41bb1a", "page": 3, "type": "paragraph", "text": "formulations alternated in weekly intervals of time"}
{"id": "9ce3f4d8-abcf-404b-862c-f406ca155629", "page": 3, "type": "paragraph", "text": "and that during each weekly interval, approxi-"}
{"id": "a2cb2341-bd45-4101-a3d8-ac1016dbc1f8", "page": 3, "type": "paragraph", "text": "mately half the facilities administered the re-"}
{"id": "00f50606-1311-4d7e-9666-9c166f072e82", "page": 3, "type": "paragraph", "text": "combinant vaccine while the other half adminis-"}
{"id": "e9f46b3a-159c-4e9e-affa-d7831ee5a45d", "page": 3, "type": "paragraph", "text": "tered a standard-dose vaccine. The format of"}
{"id": "fc5ad10e-7d52-4057-a5b9-f5bfac6bd407", "page": 3, "type": "paragraph", "text": "having alternating formulations each week at"}
{"id": "a69e3c02-fd7a-4b06-b2e0-ef1942107c53", "page": 3, "type": "paragraph", "text": "each facility was intended to emulate a random-"}
{"id": "fb852ebd-d59c-41ed-97cf-ab04843a09df", "page": 3, "type": "paragraph", "text": "ized trial in which the vaccine formulations"}
{"id": "5a5ca21b-1b32-495a-a16c-18e50f7be7ee", "page": 3, "type": "paragraph", "text": "would be randomly assigned within each facility."}
{"id": "ec8e2743-781a-48dc-be97-bb00aa7fe5da", "page": 3, "type": "paragraph", "text": "This design was intended to achieve balance"}
{"id": "b856287d-28e1-45c6-be1e-4eeb0182508d", "page": 3, "type": "paragraph", "text": "between the two vaccine groups, which would"}
{"id": "9adff801-fb11-4e73-8b17-912f07c63d46", "page": 3, "type": "paragraph", "text": "have similar distribution with respect to ob-"}
{"id": "833cb434-c867-4892-a773-28c4deae0205", "page": 3, "type": "paragraph", "text": "served and unobserved risk factors at every facil-"}
{"id": "cafdc997-5042-49e8-947c-5e0c5ea5569b", "page": 3, "type": "paragraph", "text": "ity and in the overall study population during"}
{"id": "9d7ac455-d0a4-4d20-b0e0-51f7d1232ab8", "page": 3, "type": "paragraph", "text": "Figure 1. Study Cluster Randomization, According to Service Area and Facility Size."}
{"id": "5055ad1d-71fe-458f-9f25-14b7c2e9a08d", "page": 3, "type": "paragraph", "text": "The size of each facility in the Kaiser Permanente Northern California (KPNC) health care system refers to the num-"}
{"id": "790fa06d-e069-4cb6-8bbd-baad0da1f199", "page": 3, "type": "paragraph", "text": "ber of influenza vaccines that were administered during the 2017\u20132018 influenza season immediately preceding the"}
{"id": "c8679fa6-d11e-413b-8765-69950c66dc86", "page": 3, "type": "paragraph", "text": "current study period. RIV4 denotes quadrivalent recombinant influenza vaccine, and SD-IIV4 quadrivalent standard-"}
{"id": "7a473292-47cc-4337-995e-f44e8942f859", "page": 3, "type": "paragraph", "text": "dose inactivated influenza vaccines."}
{"id": "865582d0-80a1-4b27-b4f7-9f32d792539d", "page": 3, "type": "paragraph", "text": "Facility 1"}
{"id": "bbf231c4-7efb-4124-9379-0368c9b1432d", "page": 3, "type": "paragraph", "text": "Facility 2"}
{"id": "687dc4dd-4b80-4e46-a436-eb269284f6df", "page": 3, "type": "paragraph", "text": "Facility 3"}
{"id": "f8f02c31-4dce-41f1-95cc-c7bae71b0ac6", "page": 3, "type": "paragraph", "text": "Facility 4"}
{"id": "6402cb4e-ed60-45c0-8dd4-3dab1ca38be8", "page": 3, "type": "paragraph", "text": "Facility 5"}
{"id": "8079aeff-8f64-41ea-9835-2ba38ee35c9c", "page": 3, "type": "paragraph", "text": "Facility 6"}
{"id": "f4ce3155-89f5-482e-996d-c53895674c15", "page": 3, "type": "paragraph", "text": "Facility 7"}
{"id": "209df3e3-7a06-4c95-a4fc-8aacf6f9d8f2", "page": 3, "type": "paragraph", "text": "Facility 9"}
{"id": "c6e90d79-df29-4d66-869c-9438c06a0032", "page": 3, "type": "paragraph", "text": "Facility 8"}
{"id": "6bac29c9-e11b-455c-b163-140eb5692e49", "page": 3, "type": "paragraph", "text": "2. KPNC facilities of similar size within a"}
{"id": "07ff5822-575e-4481-84cd-afcc13f766ee", "page": 3, "type": "paragraph", "text": "service area area were randomly assigned"}
{"id": "0a3803d7-1b3f-4a5f-b721-c308fa584fdc", "page": 3, "type": "paragraph", "text": "to Block A or Block B."}
{"id": "3fdb9335-7b6b-4826-9fb6-a6831bc16883", "page": 3, "type": "paragraph", "text": "Block A"}
{"id": "8bf31e35-b8db-46db-b24e-af2cd4a3f521", "page": 3, "type": "paragraph", "text": "Block B"}
{"id": "a3d996d8-014a-404d-ad07-49825b15857d", "page": 3, "type": "paragraph", "text": "1. A KPNC service area contains facilities"}
{"id": "9dc7690a-5b09-40f2-ae17-7fe328e87813", "page": 3, "type": "paragraph", "text": "of various sizes."}
{"id": "0d5f603f-fd0b-4627-8961-7436476433ea", "page": 3, "type": "paragraph", "text": "Facility 1"}
{"id": "b884b4a6-3adb-4e17-9776-9ac01cfbaf2c", "page": 3, "type": "paragraph", "text": "Facility 2"}
{"id": "7a8e36eb-b568-416d-8b6d-b71132f72bea", "page": 3, "type": "paragraph", "text": "Facility 3"}
{"id": "f9b4f1c3-c82a-442b-91eb-aeae9584a52f", "page": 3, "type": "paragraph", "text": "Facility 4"}
{"id": "e6a2455f-d977-4fea-ade9-bb971f9e3bc2", "page": 3, "type": "paragraph", "text": "Facility 5"}
{"id": "3f874704-876a-4786-b091-d34e7c2139b4", "page": 3, "type": "paragraph", "text": "Facility 6"}
{"id": "69a53ecb-5291-4154-b4ac-5ca4cd0235ee", "page": 3, "type": "paragraph", "text": "Facility 7"}
{"id": "f62f3a56-2381-4afe-92a7-4fe488dde38f", "page": 3, "type": "paragraph", "text": "Facility 8"}
{"id": "fc1cf650-f243-4c91-9ad1-6ba58d5bde8f", "page": 3, "type": "paragraph", "text": "Facility 9"}
{"id": "d5cedc22-8490-4190-a3c1-42cd059f0416", "page": 3, "type": "paragraph", "text": "Similarly sized"}
{"id": "4887ae81-7e0f-41b1-a372-68290f13b972", "page": 3, "type": "paragraph", "text": "Facilities within"}
{"id": "46b0daca-c8a3-41b1-b437-c116a8bfaf60", "page": 3, "type": "paragraph", "text": "a service area"}
{"id": "5ae3d6ae-52e2-4e50-929e-29f108be18da", "page": 3, "type": "paragraph", "text": "Week 1"}
{"id": "7d5a4c89-cf48-432c-b082-3855f20995cd", "page": 3, "type": "paragraph", "text": "Week 2"}
{"id": "abfade8f-5805-498e-8c93-8dab2a1c1e97", "page": 3, "type": "paragraph", "text": "Week 3"}
{"id": "e68aadc5-86ae-483d-ac7d-7113647381ca", "page": 3, "type": "paragraph", "text": "Week 4"}
{"id": "d348025d-83cd-4057-b563-d426c5e265f5", "page": 3, "type": "paragraph", "text": "Facility 1: Block A"}
{"id": "0f27a30c-eff6-482b-9d6b-536ac922e1e1", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "e55d5fdf-8e40-4525-9556-968842c35af8", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "005a8105-e6ba-4c29-a06a-31bec60a0cfa", "page": 3, "type": "paragraph", "text": "Facility 2: Block B"}
{"id": "506b144c-0b11-48a5-84a7-3506e6160d31", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "26500a22-7b51-4f4c-bd8d-d2757d1e81ce", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "9e8823e3-5597-44f9-8ab2-6b831de5e96d", "page": 3, "type": "paragraph", "text": "Facility 3: Block B"}
{"id": "792b1b35-9546-4c56-a142-200eb60ed7b1", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "178f9036-72cd-4acb-8cdf-64b46f8476ab", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "556633a5-0941-49d3-bb1c-5bdaf17c0072", "page": 3, "type": "paragraph", "text": "Facility 4: Block A"}
{"id": "632cd07c-9fa1-4859-afde-45fd5935db56", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "43409f86-3641-4df3-a296-014211af4721", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "07e51257-4b54-4cf3-bfa0-59bdb1e66999", "page": 3, "type": "paragraph", "text": "Facility 5: Block B"}
{"id": "0666c760-51da-4e15-8c60-b2829f5f0a96", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "41c4ed74-65f6-4966-b735-bc6ab2f6d630", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "938912e8-096b-45db-a2a3-0798c7ad274f", "page": 3, "type": "paragraph", "text": "Facility 6: Block A"}
{"id": "e021d19b-5ea9-4162-b31c-f5bd4ac4ff00", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "7d0c3e03-6b28-4cbc-869f-1d707d8d6357", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "8f3907e7-b8d2-4aa0-989d-d7fe142601a0", "page": 3, "type": "paragraph", "text": "Facility 7: Block B"}
{"id": "215792f2-012b-4ff3-8af7-70323e39c4c9", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "8934d6cc-9c32-4b37-a18e-a746c8379969", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "47097578-2376-4cc3-b7cb-ccd57a6522c4", "page": 3, "type": "paragraph", "text": "Facility 8: Block B"}
{"id": "b73dbb15-80c2-47bb-a6aa-b70dff2a0430", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "16718fa9-3f62-4906-8806-7b466e7101b2", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "1329f8e7-32bf-4e12-922a-3c0c5aa4463f", "page": 3, "type": "paragraph", "text": "Facility 9: Block A"}
{"id": "5577a776-506c-4e3d-9b0d-0d88f9720c20", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "0974c9b3-626a-4ecf-ac69-9292505d4137", "page": 3, "type": "paragraph", "text": "SD-IIV4"}
{"id": "94b71e35-d694-4103-b4f8-f9fb13ec3a50", "page": 3, "type": "paragraph", "text": "3. After Block A and Block B were assigned"}
{"id": "b3e31dd2-0ba5-41e1-ae85-05abe23363f7", "page": 3, "type": "paragraph", "text": "to SD-IIV4 or RIV4 for the first week of the"}
{"id": "d43ec11e-0724-439a-bb70-66d1c3a6f1c5", "page": 3, "type": "paragraph", "text": "influenza vaccination season, every facility"}
{"id": "dee6334f-e35b-40ee-b57d-d7b76c042578", "page": 3, "type": "paragraph", "text": "alternated formulations weekly until the"}
{"id": "8075ace5-5f9d-4662-bbcc-1ae3f1d2ec48", "page": 3, "type": "paragraph", "text": "end of the season. For illustrative purposes,"}
{"id": "a12a5328-081f-4427-9d43-2a1fae6215fd", "page": 3, "type": "paragraph", "text": "only 4 weeks of the schedule are shown."}
{"id": "3129f36d-ddca-4e02-8b16-f10ddcc92cc6", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "7f15cadd-dadc-4d34-aebf-eb95ede422c3", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "6410a2fe-1ff2-4b3e-9328-8d837a9560e2", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "c8643550-a3f8-4d6c-92c2-6d3fc1fc2151", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "b149bbc1-5f6d-4af5-9059-7c62f84200da", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "6753bea9-23b7-4ca3-93fd-0776df67e3cd", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "b66c6c28-7581-423e-aa3b-986c776c6f95", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "89315236-47bc-4dd6-ae87-85e12dbb090c", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "5b8272a6-1ee1-48c2-9639-1cab99099393", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "daa97d02-4456-4f32-b682-a391f7290dc3", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "b9e768fe-149d-4c69-8c6a-eb5d6cb69e54", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "9711941c-7f79-4070-a714-dde3af7de441", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "56efb14d-ac37-429b-857c-a5d4e8774124", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "d4de2077-8768-4289-b405-7fa0c289a677", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "b314abaf-4c5b-441d-97be-3903b27dfcc6", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "35b0d1ae-5301-4718-a039-447a0941b838", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "8fde51e6-f2d8-4214-b6de-b97be207915e", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "ed60094f-0d17-42fa-95ff-3186f2ed21e4", "page": 3, "type": "paragraph", "text": "RIV4"}
{"id": "87e9a2a2-e455-486a-b686-e940e3c05905", "page": 3, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "80c73b14-d38b-4c50-9859-b1ec46ed309f", "page": 3, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "36900ce9-9b34-4ecd-836b-85fdf15add3e", "page": 3, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "a82e8a60-4819-4a5e-a8c1-3eb477fc5785", "page": 4, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "5a76c898-e3bf-4d2d-adb1-ee607288e749", "page": 4, "type": "paragraph", "text": "2248"}
{"id": "1c55654e-acae-443b-a7a9-c38614a71a18", "page": 4, "type": "paragraph", "text": "The new engl and jour nal of medicine"}
{"id": "7176edf6-1475-43e2-ad4a-8d8b9e0e0deb", "page": 4, "type": "paragraph", "text": "the weeks when influenza was circulating. Pa-"}
{"id": "1289715a-6c05-414f-aa9c-7c9df0050e60", "page": 4, "type": "paragraph", "text": "tients were unaware of which vaccine was avail-"}
{"id": "3c6b6485-e54e-4799-89e2-3f571ef95c36", "page": 4, "type": "paragraph", "text": "able at any facility. During the study period, the"}
{"id": "42b12757-40af-44c8-ac58-dd6995c47437", "page": 4, "type": "paragraph", "text": "facilities administered primarily high-dose vac-"}
{"id": "d2718ec3-8c95-49ca-a1a7-4a7af2a29448", "page": 4, "type": "paragraph", "text": "cines to adults who were 65 years of age or"}
{"id": "5834fb09-38b4-46cd-94cf-57b746674d3c", "page": 4, "type": "paragraph", "text": "older, which made it infeasible to include those"}
{"id": "cdc20b32-bc83-4c02-8c9c-56404247d575", "page": 4, "type": "paragraph", "text": "members in the study randomization."}
{"id": "a7cb4db5-d430-4d95-87db-e7162fc56319", "page": 4, "type": "paragraph", "text": "Outcomes"}
{"id": "3414b9e5-21ee-4859-97b6-a519e1f787bb", "page": 4, "type": "paragraph", "text": "The primary outcome was influenza as con-"}
{"id": "3b2947ed-72eb-4efa-b1ed-1bcf3f0e5bb8", "page": 4, "type": "paragraph", "text": "firmed by polymerase-chain-reaction (PCR) test-"}
{"id": "edcbd53d-3a47-40ab-b352-d615e3246290", "page": 4, "type": "paragraph", "text": "ing (Cepheid GeneXpert PCR assay, a test that"}
{"id": "ae5a76df-6e04-4deb-a698-951943f51436", "page": 4, "type": "paragraph", "text": "also identifies respiratory syncytial virus [RSV])."}
{"id": "ea34b1dd-ae60-4ed5-878b-3d134ee7340c", "page": 4, "type": "paragraph", "text": "Physicians at each facility ordered influenza PCR"}
{"id": "8f26a97f-de57-49d2-be53-222d92d0e8d2", "page": 4, "type": "paragraph", "text": "tests at their discretion on the basis of clinical"}
{"id": "8575c29e-111b-4663-8ad6-8a1db857cc34", "page": 4, "type": "paragraph", "text": "presentation; rapid influenza antigen testing was"}
{"id": "43374aa4-1cd2-4daf-8fc8-4b77d4e0ad07", "page": 4, "type": "paragraph", "text": "not performed."}
{"id": "b3d113d0-0e95-4728-970b-39d5547eb140", "page": 4, "type": "paragraph", "text": "Secondary outcomes were PCR-confirmed in-"}
{"id": "e94a6297-5ce9-4e1a-b899-583823e6ccf4", "page": 4, "type": "paragraph", "text": "fluenza A, PCR-confirmed influenza B, and hos-"}
{"id": "fcae8a08-3cfb-4942-b211-d3139b87d46a", "page": 4, "type": "paragraph", "text": "pitalization for PCR-confirmed influenza, for"}
{"id": "8ac54679-cf07-4bac-8f41-fef70a9fb2f3", "page": 4, "type": "paragraph", "text": "community-acquired pneumonia, and for cardio-"}
{"id": "8df93f30-2dc2-44c0-8159-4899f6c76c22", "page": 4, "type": "paragraph", "text": "respiratory events including community-acquired"}
{"id": "8389e105-f74b-41a2-b373-da6e6307d0e9", "page": 4, "type": "paragraph", "text": "pneumonia. We identified community-acquired"}
{"id": "f9b8b5c7-2a77-4440-8872-24c3975231fb", "page": 4, "type": "paragraph", "text": "pneumonia and other cardiorespiratory events"}
{"id": "3aeec262-0c80-4515-8dff-1b9fbd16c5c0", "page": 4, "type": "paragraph", "text": "using primary discharge diagnosis codes as listed"}
{"id": "9d7064c0-98ef-480d-b9c7-29e5195135cd", "page": 4, "type": "paragraph", "text": "in the International Classification of Diseases, 10th"}
{"id": "e76afe61-d37e-469a-80f3-dbb37e213b6c", "page": 4, "type": "paragraph", "text": "Revision (ICD-10) (Table S2)."}
{"id": "b6bde9db-b635-4adb-b44b-ce7a9de0da6c", "page": 4, "type": "paragraph", "text": "Exploratory outcomes were an influenza diag-"}
{"id": "9302dc73-86f9-4415-a839-c450f10031c1", "page": 4, "type": "paragraph", "text": "nosis (PCR-confirmed or clinically diagnosed"}
{"id": "7d277025-f7ab-495c-8248-9f47f6642b25", "page": 4, "type": "paragraph", "text": "influenza on the basis of ICD-10 codes), nonelec-"}
{"id": "bd21b9e0-bc6a-4027-89e4-d2c9434dc841", "page": 4, "type": "paragraph", "text": "tive hospitalization for any cause, and death"}
{"id": "435f43fd-e6ec-41ea-b84d-4b014c9ff9e4", "page": 4, "type": "paragraph", "text": "from any cause. For each outcome except death"}
{"id": "cb20cad7-1f1c-4b9e-8c5a-1e7660db741b", "page": 4, "type": "paragraph", "text": "from any cause, we counted only the first event"}
{"id": "5300f26c-b801-4d73-9a0c-c6b959ced72d", "page": 4, "type": "paragraph", "text": "during each season that occurred more than 14"}
{"id": "7aee6ad5-a214-437c-917f-a3aabb447579", "page": 4, "type": "paragraph", "text": "days after vaccination. All deaths after vaccina-"}
{"id": "7491418d-b921-4a1a-844e-3c5a344a36b6", "page": 4, "type": "paragraph", "text": "tion within the study period were considered to"}
{"id": "c30cb6eb-f74f-43fd-b724-02ba5bc7e1bc", "page": 4, "type": "paragraph", "text": "be a safety outcome and were counted even if they"}
{"id": "42f29b71-1461-4798-b670-57f940d06214", "page": 4, "type": "paragraph", "text": "had occurred within 14 days after vaccination."}
{"id": "477fd5a7-9341-4e84-a516-9d9dafa32caa", "page": 4, "type": "paragraph", "text": "Objectives"}
{"id": "bb6774a9-a0d5-46f6-ab25-7b5f1e3d22fa", "page": 4, "type": "paragraph", "text": "The primary objective was to estimate the rela-"}
{"id": "6924bbf1-8ccd-42a9-a6d0-fec3c2c82475", "page": 4, "type": "paragraph", "text": "tive vaccine effectiveness of the recombinant vac-"}
{"id": "962629a7-c82e-4a99-8bd9-ac621a4eca87", "page": 4, "type": "paragraph", "text": "cine as compared with a standard-dose vaccine"}
{"id": "dbaa8b95-9d8f-4745-b925-b3848959fb97", "page": 4, "type": "paragraph", "text": "against PCR-confirmed influenza in patients be-"}
{"id": "f00e9142-c09a-4b92-ae2e-4bf59f9daa74", "page": 4, "type": "paragraph", "text": "tween the ages of 50 and 64 years, the primary"}
{"id": "b6c922a8-3eb2-4191-981d-929fc5f53a77", "page": 4, "type": "paragraph", "text": "age group (Table S3). The secondary objectives"}
{"id": "651a1b2b-9294-45f1-8e82-0d5038a0dd7c", "page": 4, "type": "paragraph", "text": "were to estimate the relative vaccine effective-"}
{"id": "f0a4302c-34d5-4366-b63e-fb1da28d934f", "page": 4, "type": "paragraph", "text": "ness of the recombinant vaccine against second-"}
{"id": "2a0d5032-70d4-4f66-9280-b721a3427972", "page": 4, "type": "paragraph", "text": "ary outcomes in patients in the primary age"}
{"id": "02d56695-79ad-485a-8c99-fc78b4a1c1bd", "page": 4, "type": "paragraph", "text": "group and against secondary outcomes in five"}
{"id": "6c06fb24-6e70-4e1c-bba3-afd4f4ebf454", "page": 4, "type": "paragraph", "text": "prespecified subgroups of patients with preex-"}
{"id": "ae63b8d5-bac2-4540-ad53-cde6cfee49d4", "page": 4, "type": "paragraph", "text": "isting conditions (cardiovascular disease, respi-"}
{"id": "ef650e80-7603-4420-802a-e2ade7e1f58b", "page": 4, "type": "paragraph", "text": "ratory disease, cardiorespiratory disease, obesity,"}
{"id": "9c9dfe07-9858-4224-be47-121862f9f6a3", "page": 4, "type": "paragraph", "text": "and diabetes) in the primary age group. Other"}
{"id": "3a4a8ba9-ffb4-4601-90ce-894a93bf5868", "page": 4, "type": "paragraph", "text": "estimates of relative vaccine effectiveness were"}
{"id": "b5bb9522-881f-4ee0-af93-800a3ce865ea", "page": 4, "type": "paragraph", "text": "considered to be exploratory."}
{"id": "b6c987fd-3a74-4052-a2c6-899d0e95021c", "page": 4, "type": "paragraph", "text": "Statistical Analysis"}
{"id": "150ff812-6c02-4ae4-b9c5-22901fc1b5ea", "page": 4, "type": "paragraph", "text": "We tested the null hypotheses that the recombi-"}
{"id": "aa16e821-2cac-4f3f-854c-d6837462a637", "page": 4, "type": "paragraph", "text": "nant vaccine would not be any more or any less"}
{"id": "0eab3275-33a9-4921-9a8c-cf81eeb74496", "page": 4, "type": "paragraph", "text": "effective than a standard-dose vaccine against"}
{"id": "0b8aecfe-98c7-48f7-93e5-2428bf3fce4d", "page": 4, "type": "paragraph", "text": "influenza, using a two-sided test with a P value"}
{"id": "d03a84e4-0c27-40eb-98ae-420c4cad2631", "page": 4, "type": "paragraph", "text": "of less than 0.05 indicating statistical signifi-"}
{"id": "cf95cdaf-e7ad-476b-b8dd-c3087e5f1063", "page": 4, "type": "paragraph", "text": "cance. We estimated that the administration of"}
{"id": "bc2476f6-9272-4458-be81-e6d29bce6487", "page": 4, "type": "paragraph", "text": "400,000 doses each of the two vaccine formula-"}
{"id": "5459ac26-185c-4419-8922-ed4c1ab97185", "page": 4, "type": "paragraph", "text": "tions to patients between the ages of 18 and 64"}
{"id": "3df1f689-e206-432a-b6ff-bf860f7edf75", "page": 4, "type": "paragraph", "text": "years each influenza season would provide the"}
{"id": "11778eb4-c400-4e0f-8f2f-0d18a14a4da3", "page": 4, "type": "paragraph", "text": "study with 86% power to detect a relative vaccine"}
{"id": "32210268-80b7-456c-a20e-e8a696745087", "page": 4, "type": "paragraph", "text": "effectiveness of 10.0% against PCR-confirmed"}
{"id": "1ab228be-48b9-427e-8d9b-f83af1defd45", "page": 4, "type": "paragraph", "text": "influenza. On the basis of previous data, we es-"}
{"id": "a4ac2c16-e11e-4633-b4fb-d3b1b5e9c9e6", "page": 4, "type": "paragraph", "text": "timated the occurrence of 2.18 PCR-confirmed"}
{"id": "1f6aab21-6432-4093-b236-34329f67d663", "page": 4, "type": "paragraph", "text": "influenza cases per 1000 participants in the"}
{"id": "af1fac23-0409-47fb-8d63-4861eae67c15", "page": 4, "type": "paragraph", "text": "standard-dose group."}
{"id": "c982cfbe-cbbc-42c5-b734-c7bec69e2500", "page": 4, "type": "paragraph", "text": "We used Cox regression analysis to estimate"}
{"id": "2154d66e-1ebf-491e-b1b0-72ad04a969c4", "page": 4, "type": "paragraph", "text": "the adjusted hazard ratio and 95% confidence"}
{"id": "f665ea49-c47e-44df-a7f1-aa2f355d95c5", "page": 4, "type": "paragraph", "text": "intervals for the recombinant vaccine as com-"}
{"id": "9879f0e2-4409-47f3-adb3-3a0de0bdf777", "page": 4, "type": "paragraph", "text": "pared with a standard-dose vaccine for each"}
{"id": "194df3ef-968c-4f53-9f60-4c8d95042891", "page": 4, "type": "paragraph", "text": "outcome. The model specified a calendar time"}
{"id": "a157936e-6120-4224-8d34-4553907cccb7", "page": 4, "type": "paragraph", "text": "scale and included adjustments for sex, race or"}
{"id": "aa593f84-84af-41ea-aa80-6d0c248a1c7c", "page": 4, "type": "paragraph", "text": "ethnic group, and age and an age-squared factor"}
{"id": "b1153b06-22d4-449e-b0f3-fa1de5b4681b", "page": 4, "type": "paragraph", "text": "(in case age and risk had either a linear or cur-"}
{"id": "54e4782a-a4b4-4fe7-b76a-4d0a885ede6a", "page": 4, "type": "paragraph", "text": "vilinear association). Risk sets were formed on"}
{"id": "0edb5f42-dfbb-449c-ad28-5918f33e9c7b", "page": 4, "type": "paragraph", "text": "each date on which at least one outcome event"}
{"id": "9b0517b6-f264-45d2-9c23-06869bc56947", "page": 4, "type": "paragraph", "text": "occurred in either study group. Each risk set"}
{"id": "c1b52f4a-3252-4f69-9453-5389ebdcb11c", "page": 4, "type": "paragraph", "text": "contained every participant in follow-up on that"}
{"id": "b4da82a7-75a4-45fa-8a71-e3673e8e2a38", "page": 4, "type": "paragraph", "text": "calendar date. Most of the participants had been"}
{"id": "88f96750-6999-4b4a-acea-83ffa4a8d41a", "page": 4, "type": "paragraph", "text": "vaccinated before the beginning of the influenza"}
{"id": "34387bdc-ce4c-4d53-b250-13876a86b11d", "page": 4, "type": "paragraph", "text": "season and were included in every risk set"}
{"id": "775c2fcd-87aa-4d52-89f0-e65a809d491b", "page": 4, "type": "paragraph", "text": "throughout the season."}
{"id": "4afc814c-8b94-446c-b992-e88a1a3737d7", "page": 4, "type": "paragraph", "text": "The Cox model also used stabilized weights"}
{"id": "f5a76d08-9591-4965-a783-2606084c6150", "page": 4, "type": "paragraph", "text": "that were based on propensity scores. The statis-"}
{"id": "5f82b98b-e999-4f3e-8339-5ebf14422928", "page": 4, "type": "paragraph", "text": "tical analysis plan prespecified the use of pro-"}
{"id": "261d1b09-df31-4be3-91ea-9a4a84e343ba", "page": 4, "type": "paragraph", "text": "pensity scores if imbalances were found in any"}
{"id": "7a798083-f082-47e3-999b-d8cc9afb09f9", "page": 4, "type": "paragraph", "text": "study variables. We observed modest imbalances"}
{"id": "72df7326-156e-4d68-8d87-e3175f1505c5", "page": 4, "type": "paragraph", "text": "at some facilities in one or both seasons, although"}
{"id": "96fbf410-1a1f-4dc4-acaa-bb55bf74a917", "page": 4, "type": "paragraph", "text": "not overall (Tables S4 and S5). Thus, we created"}
{"id": "f39b50fc-ab8e-4722-a5e0-829e466c645e", "page": 4, "type": "paragraph", "text": "propensity scores that were specific for each fa-"}
{"id": "cf9d092c-148b-4244-a8a4-d6662b1461fd", "page": 4, "type": "paragraph", "text": "cility and season. The propensity scores were"}
{"id": "d4abf81f-2daa-4ab4-8916-0034857f39e5", "page": 4, "type": "paragraph", "text": "derived by logistic regression to estimate the"}
{"id": "6f7476c2-6bf1-4b26-abf4-a9657efd7a1b", "page": 4, "type": "paragraph", "text": "probability of the receipt of a recombinant vac-"}
{"id": "832454fa-a30b-4feb-a062-4f5ecceca5f7", "page": 4, "type": "paragraph", "text": "cine rather than a standard-dose vaccine with"}
{"id": "4a75bb5d-6abd-45fc-9543-690defd89c1b", "page": 4, "type": "paragraph", "text": "respect to sex, race, age, coexisting illnesses,"}
{"id": "d326bc0b-b1de-421e-a35b-ac53eddea914", "page": 4, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "89967484-65a6-40e3-834f-575207ccb989", "page": 4, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "b88cc36a-84fc-4b7f-acc3-de8dce1457cb", "page": 4, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "835e8b9a-5a3c-431a-b5d0-18ccffb6244a", "page": 5, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "16b9aefb-083e-40a4-b326-d7ce4ad65bcd", "page": 5, "type": "paragraph", "text": "2249"}
{"id": "2d0452b5-5e73-4237-90e1-10267a418e85", "page": 5, "type": "paragraph", "text": "Recombinant or Standard-Dose Influenza Vaccine"}
{"id": "c7c4faf8-e616-499d-a7e2-e6a3cfc601ef", "page": 5, "type": "paragraph", "text": "indicators of health care\u2013seeking behavior (e.g.,"}
{"id": "ac0e893b-389a-41dc-b74b-3e084f805cf7", "page": 5, "type": "paragraph", "text": "previous influenza vaccination), 2-month inter-"}
{"id": "567babff-2157-4771-b4fd-b85b85fb9880", "page": 5, "type": "paragraph", "text": "vals of calendar time, and other factors. Missing"}
{"id": "24c1e324-7f0a-4a5d-8df0-6eadb86df551", "page": 5, "type": "paragraph", "text": "data were not imputed."}
{"id": "08cd9b90-4e42-42f9-8793-0c7404497f78", "page": 5, "type": "paragraph", "text": "The relative vaccine effectiveness was based"}
{"id": "4092c811-77c0-43bd-92fe-28c378c210dd", "page": 5, "type": "paragraph", "text": "on the hazard ratio (1 minus the hazard ratio,"}
{"id": "b18ba892-cdaf-49d4-8c8c-72a339a617a3", "page": 5, "type": "paragraph", "text": "expressed as a percentage). This calculation es-"}
{"id": "b68f775e-1ba6-4e65-8eac-59b20f421d1d", "page": 5, "type": "paragraph", "text": "timated the percent reduction in the incidence of"}
{"id": "8e9a62a8-e838-4c90-8dd8-d81b7eca1167", "page": 5, "type": "paragraph", "text": "the outcome in the recombinant-vaccine group"}
{"id": "81ca6afe-1ab7-4b00-9390-fc09b2693188", "page": 5, "type": "paragraph", "text": "as compared with that in the standard-dose"}
{"id": "fbfa602c-0150-4967-9551-21f43f9aac62", "page": 5, "type": "paragraph", "text": "group. The proportional-hazards assumption of"}
{"id": "972080d9-ab32-497a-9f6c-cda182c9fa87", "page": 5, "type": "paragraph", "text": "the Cox regression was evaluated, and no viola-"}
{"id": "befa800f-1c46-4752-9a83-358a55c8b994", "page": 5, "type": "paragraph", "text": "tion was found (Fig. S1)."}
{"id": "efa71503-9245-4c32-9fff-5e01bcf78493", "page": 5, "type": "paragraph", "text": "For secondary objectives in participants be-"}
{"id": "c7bae841-2f9a-483b-b37b-8dad4670d992", "page": 5, "type": "paragraph", "text": "tween the ages of 50 and 64 years, we adjusted"}
{"id": "0953d86c-5a6f-4f0f-b8ce-4fdc13f4c13a", "page": 5, "type": "paragraph", "text": "for multiplicity by Holm\u2019s method.10 Subgroup"}
{"id": "e996485b-9f6c-43cf-8b00-ac6397485dd3", "page": 5, "type": "paragraph", "text": "analyses involving participants with preexisting"}
{"id": "ab9e42f1-16c7-4240-92a0-a4616c98b143", "page": 5, "type": "paragraph", "text": "conditions were not adjusted for multiplicity. We"}
{"id": "76e5e119-b9f2-4402-af55-f46f2a033a72", "page": 5, "type": "paragraph", "text": "conducted sensitivity analyses in which we used"}
{"id": "39bcd53e-d1a3-49fe-82f7-f1ed43fb3b6d", "page": 5, "type": "paragraph", "text": "propensity scores in alternative ways, used a robust"}
{"id": "887c0317-ffb4-4a77-b2f6-3a55d682a0eb", "page": 5, "type": "paragraph", "text": "variance estimator, stratified risk sets according"}
{"id": "0bdf1dc4-dea4-4824-b896-08c2e9d1ce3b", "page": 5, "type": "paragraph", "text": "to facility and vaccination week, and specified"}
{"id": "2431631e-97d3-40ac-b2f3-c66ada9dc10a", "page": 5, "type": "paragraph", "text": "age as a spline (see the Supplementary Methods"}
{"id": "ede3d3d7-d335-406e-adf1-3b837e8463d0", "page": 5, "type": "paragraph", "text": "section)."}
{"id": "f0de4ae9-2b19-4ab7-9141-128efd27dab6", "page": 5, "type": "paragraph", "text": "To assess possible residual confounding, we"}
{"id": "d8e26b97-5792-42a8-9247-76e91ebf5a72", "page": 5, "type": "paragraph", "text": "examined PCR-confirmed RSV infection as a"}
{"id": "3f1a1dcb-6608-473b-aed8-1dac2f136b77", "page": 5, "type": "paragraph", "text": "negative control outcome because we would not"}
{"id": "2b04564b-9d46-428b-baeb-219e2e5a9905", "page": 5, "type": "paragraph", "text": "expect influenza vaccination to be associated with"}
{"id": "719e1965-9eb3-48c5-8d17-46b7f9a864aa", "page": 5, "type": "paragraph", "text": "a reduction in this infection. A nontrivial asso-"}
{"id": "de7f86c7-98c3-4f7d-bfb0-f7408bb177ef", "page": 5, "type": "paragraph", "text": "ciation between receipt of the recombinant vac-"}
{"id": "1218e5e4-54ad-42dc-8803-9288eb7a05c1", "page": 5, "type": "paragraph", "text": "cine and RSV infection would suggest bias in"}
{"id": "c32c5318-8557-45da-843f-67ccc9db1459", "page": 5, "type": "paragraph", "text": "our estimate of the relative vaccine effectiveness"}
{"id": "c07b41c1-163f-47a1-bd1e-298d5dbd14dc", "page": 5, "type": "paragraph", "text": "against influenza. Conversely, a finding of no"}
{"id": "c3b1e510-d7a0-4aad-b395-c2b0d6b738e4", "page": 5, "type": "paragraph", "text": "association between receipt of the recombinant"}
{"id": "a6c10082-423a-4d40-8293-873889703955", "page": 5, "type": "paragraph", "text": "vaccine and RSV infection would be reassuring"}
{"id": "b8272901-18c5-4ba6-aaef-1e4d1ec49368", "page": 5, "type": "paragraph", "text": "that our estimates of relative vaccine effective-"}
{"id": "eb3e5401-ab89-47de-b1eb-fb38ef72ca92", "page": 5, "type": "paragraph", "text": "ness were not biased by unmeasured factors that"}
{"id": "f05304fd-9c25-4150-ae7b-36d3cf97f1ae", "page": 5, "type": "paragraph", "text": "might affect the risk of both laboratory-con-"}
{"id": "19729d54-9ceb-4b84-935b-e4ae55282882", "page": 5, "type": "paragraph", "text": "firmed RSV infection and influenza. All data"}
{"id": "9f84d514-07d8-4b91-ba1c-43e16d46745f", "page": 5, "type": "paragraph", "text": "analyses were performed with the use of SAS"}
{"id": "6339231e-3a88-4485-8651-4efa30b624db", "page": 5, "type": "paragraph", "text": "software, version 9.4 (SAS Institute)."}
{"id": "a27b001b-e6b0-435a-a0ff-c65353d7456c", "page": 5, "type": "paragraph", "text": "Results"}
{"id": "717f2f38-5f46-4ac2-8fa5-a61e4e9866f0", "page": 5, "type": "paragraph", "text": "Study Participants"}
{"id": "1974a6b0-80f5-4ae0-b7e2-cbbfefa4001b", "page": 5, "type": "paragraph", "text": "The study population included 1,630,328 partici-"}
{"id": "a7da9fc5-390d-455b-85ad-351fc47aab4a", "page": 5, "type": "paragraph", "text": "pants during influenza seasons in 2018\u20132019 and"}
{"id": "1ad707c3-8ae6-44e0-8c2f-843b502be991", "page": 5, "type": "paragraph", "text": "2019\u20132020. Of these participants, 632,962 (38.8%)"}
{"id": "d5bd675f-fe9f-4b35-91ab-13355ece7460", "page": 5, "type": "paragraph", "text": "received the recombinant vaccine and 997,366"}
{"id": "748e03c8-6026-41e8-a0ad-f302f6b60126", "page": 5, "type": "paragraph", "text": "(61.2%) received a standard-dose vaccine (Fig. 2"}
{"id": "eaaf026c-e455-40f9-99f0-46c2387bfae9", "page": 5, "type": "paragraph", "text": "and Table S6). In both seasons, delays in ship-"}
{"id": "a395358d-2e26-49e7-8395-1f32152f6e82", "page": 5, "type": "paragraph", "text": "ments of the recombinant vaccine occasionally"}
{"id": "e6ed5554-31bc-4880-a634-fbc6a8a0d447", "page": 5, "type": "paragraph", "text": "left some clinics temporarily without enough"}
{"id": "f87985bf-bc56-446a-a55d-6ada10d03ebf", "page": 5, "type": "paragraph", "text": "recombinant vaccine to comply with the week-"}
{"id": "09231a8f-3925-43ef-8b22-d39f181b65ef", "page": 5, "type": "paragraph", "text": "ly schedule, so standard-dose vaccines were"}
{"id": "9a45d14f-8e47-4556-a9f1-66a62f859ba0", "page": 5, "type": "paragraph", "text": "then administered to prevent interruptions in"}
{"id": "a2324de9-227d-4875-84c6-b435a66a408b", "page": 5, "type": "paragraph", "text": "patient care."}
{"id": "9750d24a-bf15-439a-b18b-7c986d952dcf", "page": 5, "type": "paragraph", "text": "Among the 675,252 patients between 50 and"}
{"id": "bbaa8a01-893b-41df-aa03-0ff242d7e9c8", "page": 5, "type": "paragraph", "text": "64 years of age, 279,400 (41.4%) received the"}
{"id": "67855f17-7791-4a8e-a71a-bdaf22e47875", "page": 5, "type": "paragraph", "text": "recombinant vaccine and 395,852 (58.6%) re-"}
{"id": "437310e5-3f87-400b-ae46-f731a5505b1d", "page": 5, "type": "paragraph", "text": "ceived a standard-dose vaccine (Table 1). Among"}
{"id": "c4ba968a-a53d-44b4-b242-675c531d9594", "page": 5, "type": "paragraph", "text": "the 955,076 patients between 18 and 49 years of"}
{"id": "780fbb78-335b-4af9-8a14-9dd6c45b95eb", "page": 5, "type": "paragraph", "text": "age, 353,562 (37.0%) received the recombinant"}
{"id": "bfd55c51-b085-4591-87ed-53673b7e280b", "page": 5, "type": "paragraph", "text": "vaccine and 601,514 (63.0%) received a standard-"}
{"id": "f09f0ba0-f519-43ac-9a4a-77cc85dc9ce2", "page": 5, "type": "paragraph", "text": "dose vaccine (Table S6)."}
{"id": "a4e9081a-22a3-48df-99ac-e5633a30737d", "page": 5, "type": "paragraph", "text": "Of the 16,340 influenza PCR tests performed"}
{"id": "953e32f1-f42d-4469-bbe9-7dcaf5cc0f3d", "page": 5, "type": "paragraph", "text": "in the study population, 3821 (23.4%) were in-"}
{"id": "2d1f0401-6baf-4479-97c5-4898acc6a019", "page": 5, "type": "paragraph", "text": "fluenza positive. Of the PCR-confirmed influ-"}
{"id": "617ed654-44ca-44df-968f-90bb6b6891ad", "page": 5, "type": "paragraph", "text": "enza cases, 1484 (38.8%) were diagnosed in pa-"}
{"id": "b58f9e13-d26c-4c16-87d1-08053d5bc9a5", "page": 5, "type": "paragraph", "text": "tients between the ages of 50 and 64 years and"}
{"id": "c2040a79-7de4-404f-b6b4-b0f5025d53c5", "page": 5, "type": "paragraph", "text": "2337 (61.2%) in patients between the ages of 18"}
{"id": "1ffb6c58-d17d-472c-8fdd-94fa7ef6e159", "page": 5, "type": "paragraph", "text": "and 49 years. Among the participants with PCR-"}
{"id": "87d33af1-8ff3-4f11-acde-45e31b61e174", "page": 5, "type": "paragraph", "text": "confirmed influenza, hospitalization occurred"}
{"id": "50b425d6-f627-437c-a692-14c670932cdd", "page": 5, "type": "paragraph", "text": "in 248 of 1484 participants (16.7%) among those"}
{"id": "25988fd2-b8d9-480f-ae5a-9da5cfcf10bf", "page": 5, "type": "paragraph", "text": "between the ages of 50 and 64 years and in 136"}
{"id": "097a72fc-72e4-4a99-9048-68bb01719f9f", "page": 5, "type": "paragraph", "text": "of 2337 (5.8%) of those between the ages of 18"}
{"id": "7c1092c4-5aeb-4e47-901f-d9aafe200818", "page": 5, "type": "paragraph", "text": "and 49 years."}
{"id": "85bb44d9-8731-4366-8a3e-fb2eb8485f0b", "page": 5, "type": "paragraph", "text": "The demographic characteristics of the par-"}
{"id": "6273bcbc-fd47-4f75-beec-1cd00534297b", "page": 5, "type": "paragraph", "text": "ticipants at baseline were similar in the two vac-"}
{"id": "0935773d-3389-4a11-a129-03352dcf9442", "page": 5, "type": "paragraph", "text": "cine groups and in the two age groups (Table 1"}
{"id": "8bf3bcee-2669-4c08-bb59-80b421c1c6d3", "page": 5, "type": "paragraph", "text": "and Table S6). There was some variation in the"}
{"id": "bb43c1b1-612d-4393-942f-2cc1df8852b3", "page": 5, "type": "paragraph", "text": "timing of the administration of the two vaccines"}
{"id": "9ad5f7f2-ce5c-47e3-a718-6f6595d990ca", "page": 5, "type": "paragraph", "text": "according to geographic region, although during"}
{"id": "0ab4edaa-f482-47c4-ae00-fa84ca8e23c1", "page": 5, "type": "paragraph", "text": "the two influenza seasons, most vaccinations"}
{"id": "a3e7e663-617d-4ec5-87bc-59c22b144084", "page": 5, "type": "paragraph", "text": "in the two groups had occurred by mid-to-late"}
{"id": "cbb720ac-e23c-496a-8271-beeb25685098", "page": 5, "type": "paragraph", "text": "November (Tables S4 and S5)."}
{"id": "d7a567b8-8b01-4099-8f9b-a1f40777eeee", "page": 5, "type": "paragraph", "text": "Primary and Secondary Analyses"}
{"id": "884c3efc-f824-440b-b1d5-d4174e31d37b", "page": 5, "type": "paragraph", "text": "In patients between the ages of 50 and 64 years,"}
{"id": "1ce9cb63-875c-41a2-ac32-52eac4a5e856", "page": 5, "type": "paragraph", "text": "559 (2.00 cases per 1000) tested positive for in-"}
{"id": "0b188612-6069-40b6-b535-bbd1d83d8d16", "page": 5, "type": "paragraph", "text": "fluenza in the recombinant-vaccine group as"}
{"id": "f16504bb-cf8d-4524-832a-1d53cfefc190", "page": 5, "type": "paragraph", "text": "compared with 925 (2.34 per 1000) in the stan-"}
{"id": "611384fe-bafe-4e48-8961-d1f2af0ad606", "page": 5, "type": "paragraph", "text": "dard-dose group (Table 2). For the primary ob-"}
{"id": "fa6c6b50-05e0-4516-8b92-e5b45a6a7f46", "page": 5, "type": "paragraph", "text": "jective, the relative vaccine effectiveness of the"}
{"id": "9b40f034-9bb0-4b18-b0ab-83572ca5b377", "page": 5, "type": "paragraph", "text": "recombinant vaccine as compared with standard-"}
{"id": "2d715f0e-ed51-4977-b5d9-e34f891b349a", "page": 5, "type": "paragraph", "text": "dose vaccines against all PCR-confirmed influ-"}
{"id": "93ec06aa-1bc8-49f7-9235-ab21933645de", "page": 5, "type": "paragraph", "text": "enza was 15.3% (95% CI, 5.9 to 23.8; P = 0.002)."}
{"id": "f71d620c-9225-4b37-b147-39a8aa9c1eae", "page": 5, "type": "paragraph", "text": "The estimate of relative vaccine effectiveness"}
{"id": "4a8b407d-18e6-44f2-a77b-8823be5851d9", "page": 5, "type": "paragraph", "text": "for the secondary objective of PCR-confirmed"}
{"id": "4d451c88-8094-4533-a988-075be1fe5d8d", "page": 5, "type": "paragraph", "text": "influenza A was 15.7% (95% CI, 6.0 to 24.5;"}
{"id": "89e9447b-c02d-4a9b-a8c8-6c8b3b66ddca", "page": 5, "type": "paragraph", "text": "P = 0.002; the P value was below Holm\u2019s multi-"}
{"id": "ffdfe5f8-9d51-4d46-9737-8c7047273151", "page": 5, "type": "paragraph", "text": "plicity-adjusted threshold of an alpha level of"}
{"id": "b6ffc4fb-4b2a-436c-a825-f7f9927d4c8c", "page": 5, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "4dab3403-ad11-431a-b2eb-dcc086d6ec0a", "page": 5, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "02bfbc7d-9363-49b2-9e27-e26da5db58d6", "page": 5, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "b6a5fe39-59fd-45da-80eb-4ca51f3119b4", "page": 6, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "7651600e-a15e-4e49-8012-b3a25b356499", "page": 6, "type": "paragraph", "text": "2250"}
{"id": "fd74580a-2378-4227-afa5-b1a3eaf9417b", "page": 6, "type": "paragraph", "text": "The new engl and jour nal of medicine"}
{"id": "9317c847-bd47-4fd1-bdee-79708838fa92", "page": 6, "type": "paragraph", "text": "Figure 2. Vaccinated Adults in the Study Population (2018\u20132021)."}
{"id": "45b287a1-97a1-474b-9a37-b12a971ab545", "page": 6, "type": "paragraph", "text": "Shown is the final cohort of study participants between 18 and 64 years of age after the application of exclusion criteria. Patients who"}
{"id": "60662d86-e6fc-40e3-b33e-2db9d1835158", "page": 6, "type": "paragraph", "text": "were vaccinated as inpatients were excluded from the study because such influenza vaccinations could not be included in the random-"}
{"id": "d59a8bf2-c8b9-44ac-9a9c-2ad03540d2d8", "page": 6, "type": "paragraph", "text": "ization. The eligible date ranges for influenza vaccinations were September 17, 2018, to April 21, 2019; September 3, 2019, to February"}
{"id": "d7df1df5-3a4f-4822-808c-15f9c7f6180f", "page": 6, "type": "paragraph", "text": "25, 2020; and August 31, 2020, to April 8, 2021. In some cases, data were excluded from the analyses because records did not indicate"}
{"id": "94f374f6-541c-49e1-bbdb-f3bf4c5f0c3b", "page": 6, "type": "paragraph", "text": "the location of the facility where the vaccine had been administered. Propensity scores were derived by logistic regression to estimate"}
{"id": "ca8e1fed-38b6-4294-b740-30eda207f3eb", "page": 6, "type": "paragraph", "text": "the probability of the receipt of a recombinant vaccine rather than a standard-dose vaccine with respect to sex, race, age, coexisting ill-"}
{"id": "dc5d72bf-3c96-4ef1-8636-2c3f7f715b51", "page": 6, "type": "paragraph", "text": "nesses, indicators of health care\u2013seeking behavior, 2-month intervals of calendar time, and other factors. Some patients were vaccinated at"}
{"id": "e475f89c-88de-44cf-afdf-c8823f473737", "page": 6, "type": "paragraph", "text": "facilities where the data were too sparse to generate a facility-specific propensity score. Data for the third influenza season (2020\u20132021)"}
{"id": "4605910b-cc6b-417f-8316-518540605b2c", "page": 6, "type": "paragraph", "text": "were not included in the study because of virtually no circulation of influenza virus during the first year of the coronavirus disease 2019"}
{"id": "3233718d-6d37-4572-b4d2-223b1f398911", "page": 6, "type": "paragraph", "text": "pandemic."}
{"id": "50842465-af66-4b5f-a9bd-370cceca5a8f", "page": 6, "type": "paragraph", "text": "2,776,278 Participants 18\u201364 yr of age were vaccinated"}
{"id": "73f68707-8cc2-4246-805b-470e1fd0dd48", "page": 6, "type": "paragraph", "text": "864,503 Were vaccinated in 2018\u20132019 season"}
{"id": "7993ec9d-f542-48c1-8276-28c4388695d0", "page": 6, "type": "paragraph", "text": "944,692 Were vaccinated in 2019\u20132020 season"}
{"id": "3083d05d-1e82-4480-9d5f-ecc61bd34ead", "page": 6, "type": "paragraph", "text": "967,083 Were vaccinated in 2020\u20132021 season"}
{"id": "c5ee3586-e17e-4a8f-84bb-7c80ffad2af7", "page": 6, "type": "paragraph", "text": "1,018,043 Received recombinant vaccine"}
{"id": "e4c0aee0-00cd-433e-8d09-52497c41768a", "page": 6, "type": "paragraph", "text": "1,758,235 Received a standard-dose vaccine"}
{"id": "6c23b867-bba0-4d5d-88d4-a153307d5f8f", "page": 6, "type": "paragraph", "text": "33,133 Were not KPNC members"}
{"id": "24d6db3e-d076-4a2a-8cef-f4807e2c16d9", "page": 6, "type": "paragraph", "text": "at time of vaccination"}
{"id": "e71238f5-513e-4ffb-b11d-7c1fbf9b774e", "page": 6, "type": "paragraph", "text": "66,632 Were not KPNC members"}
{"id": "98c859ff-5cd1-4627-b7a1-b90b3a1bad34", "page": 6, "type": "paragraph", "text": "at time of vaccination"}
{"id": "1bc6da1e-6fa3-4f38-bc51-b67112dc9f85", "page": 6, "type": "paragraph", "text": "N=984,910"}
{"id": "84d5f8d3-b90c-4d57-af7d-870cacfd7612", "page": 6, "type": "paragraph", "text": "N=1,691,603"}
{"id": "ba6a863c-e6e2-485f-a6e8-1d714d585ee7", "page": 6, "type": "paragraph", "text": "440 Received inpatient"}
{"id": "8dbaee0b-ecab-4a6f-a52d-1ed25d89a91a", "page": 6, "type": "paragraph", "text": "vaccinations"}
{"id": "36ab17ca-d0e3-4e6d-8d36-4608c6189a1a", "page": 6, "type": "paragraph", "text": "18,329 Received inpatient"}
{"id": "2e0a2c31-bd33-425f-af3d-cdb1d497df92", "page": 6, "type": "paragraph", "text": "vaccinations"}
{"id": "c8a73096-6d9d-43be-b2ec-8bf7de96b4e2", "page": 6, "type": "paragraph", "text": "N=984,470"}
{"id": "fb540c7a-5c2b-4e1f-a90b-7ff551995c00", "page": 6, "type": "paragraph", "text": "N=1,673,274"}
{"id": "f8158f2d-e9b4-437a-88f0-3b228129ee1d", "page": 6, "type": "paragraph", "text": "14,556 Were vaccinated outside"}
{"id": "b3a25e6e-16fa-4235-94fa-7385f5b47408", "page": 6, "type": "paragraph", "text": "of eligible date range"}
{"id": "f51aa4a7-5e95-446d-914e-dd7b7e47a755", "page": 6, "type": "paragraph", "text": "27,857 Were vaccinated outside"}
{"id": "c6372370-5394-4fe0-a824-2b38607ca196", "page": 6, "type": "paragraph", "text": "of eligible date range"}
{"id": "6b78f774-e6a2-4d72-86be-162a38e4f3aa", "page": 6, "type": "paragraph", "text": "N=969,914"}
{"id": "114068f9-c158-412b-b16e-c5f67dc5b5c5", "page": 6, "type": "paragraph", "text": "N=1,645,417"}
{"id": "b1440a4d-2736-4090-b648-b5eed30dac31", "page": 6, "type": "paragraph", "text": "31,313 Had no facility identifier"}
{"id": "e55fdf80-8335-4b8a-90a8-aaaf7f85ad40", "page": 6, "type": "paragraph", "text": "51,812 Had no facility identifier"}
{"id": "af1e3894-5dee-4904-9ef7-53959c7a25f9", "page": 6, "type": "paragraph", "text": "N=938,601"}
{"id": "e0f8dcb8-35bd-447a-bb30-3c867770fad7", "page": 6, "type": "paragraph", "text": "N=1,593,605"}
{"id": "82a158b9-752e-41a6-b4a7-fad1d7eecaef", "page": 6, "type": "paragraph", "text": "5208 Could not be assigned a facility-"}
{"id": "7c4620b1-c151-45d2-bd2b-8291b5380f40", "page": 6, "type": "paragraph", "text": "specific propensity score"}
{"id": "426de9cc-00dc-4110-9573-fc0d0f6842ea", "page": 6, "type": "paragraph", "text": "1857 Could not be assigned a facility-"}
{"id": "a01e27f1-4a68-454b-8243-062b5b0d52c6", "page": 6, "type": "paragraph", "text": "specific propensity score"}
{"id": "e06bfa07-5f4c-4723-bc82-616b52967d8e", "page": 6, "type": "paragraph", "text": "N=936,744"}
{"id": "6db83771-a8bb-4602-9df9-86491e8f5ac0", "page": 6, "type": "paragraph", "text": "N=1,588,397"}
{"id": "80be0571-a085-4a6a-8283-fc7e1ce5b24b", "page": 6, "type": "paragraph", "text": "591,031 Were vaccinated during"}
{"id": "c088b465-4664-469e-a097-e41c29b2abc7", "page": 6, "type": "paragraph", "text": "the 2020\u20132021 season"}
{"id": "4b46ea06-8b48-4695-92fa-42c1eb806935", "page": 6, "type": "paragraph", "text": "303,782 Were vaccinated during"}
{"id": "ed195ed3-cd3f-407d-8785-4c3c5b78780f", "page": 6, "type": "paragraph", "text": "the 2020\u20132021 season"}
{"id": "897b3ff8-67e1-454f-9c55-6885357424c6", "page": 6, "type": "paragraph", "text": "632,962 Were included in the final cohort"}
{"id": "c83b2c80-3250-46e9-92e8-a9ba43c5b1a1", "page": 6, "type": "paragraph", "text": "353,562 Were 18\u201349 yr of age"}
{"id": "49fd4253-184d-4e94-a688-82794592a8e9", "page": 6, "type": "paragraph", "text": "279,400 Were 50\u201364 yr of age"}
{"id": "b9108915-a99e-45ef-9b93-e5232e96e37c", "page": 6, "type": "paragraph", "text": "997,366 Were included in the final cohort"}
{"id": "b92ebcc6-2f54-406e-927e-02f239a3ec02", "page": 6, "type": "paragraph", "text": "601,514 Were 18\u201349 yr of age"}
{"id": "e5293fc7-dff7-47b2-8e8b-9555cf78c4a1", "page": 6, "type": "paragraph", "text": "395,852 Were 50\u201364 yr of age"}
{"id": "d66a6665-3d38-42bd-803e-da381dc366b0", "page": 6, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "a826f1df-0e09-4eb3-a673-abae6e67b063", "page": 6, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "768a71ca-89fc-4f63-bf71-3ef05cc99e02", "page": 6, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "7f0ae7dc-9413-4b4e-9e2a-3b61cee24147", "page": 7, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "362504c3-089c-4cf4-88c5-3caa4561448b", "page": 7, "type": "paragraph", "text": "2251"}
{"id": "2934bd17-0497-451e-968b-5b0211a61fba", "page": 7, "type": "paragraph", "text": "Recombinant or Standard-Dose Influenza Vaccine"}
{"id": "e603655c-80f3-4001-9ef3-b9b8abddb0bc", "page": 7, "type": "paragraph", "text": "0.01) (Table 2). For outcomes involving hospital-"}
{"id": "ef9f5677-bb74-4090-b92d-a1b5b383e7f5", "page": 7, "type": "paragraph", "text": "ization, the recombinant vaccine was not sig-"}
{"id": "87d3c054-83b1-46c4-8403-72ac8f3f49e9", "page": 7, "type": "paragraph", "text": "nificantly more effective than the standard-dose"}
{"id": "96a564d1-251f-4ac0-b53b-20c2e2757dca", "page": 7, "type": "paragraph", "text": "vaccines, although the point estimate was 15.9%"}
{"id": "389b5dca-6780-4194-ba70-dfcac1a74fd6", "page": 7, "type": "paragraph", "text": "for hospitalization for PCR-confirmed influenza"}
{"id": "c7e28bc7-6300-409b-9b7f-7e77a39ac58f", "page": 7, "type": "paragraph", "text": "and 16.7% for hospitalization for community-"}
{"id": "6f646731-0d68-4716-8d83-b13c40f01a0a", "page": 7, "type": "paragraph", "text": "acquired pneumonia (Table 2). Post hoc analysis"}
{"id": "c15c3423-c39a-41fe-b84d-93e9132f375b", "page": 7, "type": "paragraph", "text": "of these two hospitalization outcomes combined"}
{"id": "24478647-1c3e-45d7-b14c-880db9db5483", "page": 7, "type": "paragraph", "text": "yielded an estimate for relative vaccine effective-"}
{"id": "d5081137-29d0-4666-9d83-177d5b5c6c81", "page": 7, "type": "paragraph", "text": "ness of 19.7% (95% CI, 2.8 to 33.7)."}
{"id": "fe996044-f794-4761-85c3-6bb48c1be307", "page": 7, "type": "paragraph", "text": "Subgroup and Exploratory Analyses"}
{"id": "2849e3c2-17e2-46b7-abb5-7ec667ec5076", "page": 7, "type": "paragraph", "text": "In subgroup analyses among participants in the"}
{"id": "e14b78ff-fd5f-4717-a40c-bf18e44be040", "page": 7, "type": "paragraph", "text": "older age group (50 to 64 years) with any of the"}
{"id": "58324e19-2567-47fb-b387-777bd12e5c11", "page": 7, "type": "paragraph", "text": "five prespecified preexisting conditions, the only"}
{"id": "525b5ac3-c450-44dd-933b-92416cd2c4b3", "page": 7, "type": "paragraph", "text": "measure of relative vaccine effectiveness that"}
{"id": "1ff7170a-4f55-4c9a-ac8e-cfa727f2cb5b", "page": 7, "type": "paragraph", "text": "significantly differed from zero was against"}
{"id": "2333daa0-b415-46bf-96c5-516987bbd9ae", "page": 7, "type": "paragraph", "text": "PCR-confirmed influenza B in the subgroup"}
{"id": "1bb3f4e2-3b6a-400b-9143-83cd510cfce8", "page": 7, "type": "paragraph", "text": "with respiratory conditions (relative vaccine ef-"}
{"id": "53c54781-6ddb-40af-92c3-bab7a4d37939", "page": 7, "type": "paragraph", "text": "fectiveness, 78.2%; 95% CI, 3.1 to 95.1) (Table"}
{"id": "910b39f0-cdf1-42fe-8a0b-ac86d0a5f33f", "page": 7, "type": "paragraph", "text": "S7). In post hoc analyses among participants in"}
{"id": "21201047-cc05-4b52-85dd-57ded98de22a", "page": 7, "type": "paragraph", "text": "the same age subgroup with any of the pre-"}
{"id": "c1ed626d-486e-4158-b3ef-ceafe188ec4d", "page": 7, "type": "paragraph", "text": "specified preexisting conditions, measures of"}
{"id": "459e12b4-049e-450f-a205-40dcd9689cf0", "page": 7, "type": "paragraph", "text": "relative vaccine effectiveness were 14.3% (95%"}
{"id": "41768e84-9307-4a0f-91a4-7edc4b859a52", "page": 7, "type": "paragraph", "text": "CI, 2.4 to 24.8) for PCR-confirmed influenza and"}
{"id": "485f4798-f052-4c63-bba4-0646e645263e", "page": 7, "type": "paragraph", "text": "14.9% (95% CI, 2.6 to 25.7) for influenza A in-"}
{"id": "5f55602f-6279-4135-9f4c-4e771d8dc824", "page": 7, "type": "paragraph", "text": "fection (Fig. 3 and Table S7)."}
{"id": "3b3664a6-13c3-4416-89a9-59c425825297", "page": 7, "type": "paragraph", "text": "Among participants in the younger age group"}
{"id": "c327b3dc-114b-4784-9a5b-8f09009a9358", "page": 7, "type": "paragraph", "text": "(18 to 49 years), 827 (2.34 cases per 1000) tested"}
{"id": "e5800ab5-4bff-4edc-8447-677ddcb88da8", "page": 7, "type": "paragraph", "text": "positive for influenza in the recombinant-vac-"}
{"id": "e5c1a07b-52ab-4746-8a62-00ed73ebaf7c", "page": 7, "type": "paragraph", "text": "Table 1. Characteristics of the Participants at Baseline (50 to 64 Years of Age).*"}
{"id": "fb995c9f-e9e1-4d7c-9600-9cac92fee57b", "page": 7, "type": "paragraph", "text": "Characteristic"}
{"id": "a6f8b722-e8c6-42d2-a557-bce430753b19", "page": 7, "type": "paragraph", "text": "Recombinant"}
{"id": "86fe7ca1-d986-41a4-b651-0119e788d990", "page": 7, "type": "paragraph", "text": "Vaccine"}
{"id": "42874455-8741-411a-b3c1-539b38a576d0", "page": 7, "type": "paragraph", "text": "(N = 279,400)"}
{"id": "c6f7837b-bf36-463a-983b-1c231f8663f7", "page": 7, "type": "paragraph", "text": "Standard-Dose"}
{"id": "ca984d38-feff-400a-86a8-e680825a65a6", "page": 7, "type": "paragraph", "text": "Vaccine"}
{"id": "ffddf171-a72f-4211-8f15-8baec3088509", "page": 7, "type": "paragraph", "text": "(N = 395,852)"}
{"id": "770ea946-362f-4620-95a2-6dc31f36595c", "page": 7, "type": "paragraph", "text": "All Vaccinees"}
{"id": "f4ceaaa3-f70f-4f49-90f0-5dbf1a53859f", "page": 7, "type": "paragraph", "text": "(N = 675,252)"}
{"id": "190bae25-cc57-484e-a8ed-f21fc5704e72", "page": 7, "type": "paragraph", "text": "no. of participants (%)"}
{"id": "adc6346e-f3a4-4daf-b283-d96abea9867a", "page": 7, "type": "paragraph", "text": "Sex \u2014 no. (%)"}
{"id": "cac7d4cf-8d41-4c85-8e85-378653a711ca", "page": 7, "type": "paragraph", "text": "Male"}
{"id": "2eebf005-7854-44d9-a897-5d59fbfaa166", "page": 7, "type": "paragraph", "text": "124,540 (45)"}
{"id": "70b0ceec-d6af-425f-8791-e1887c93bba1", "page": 7, "type": "paragraph", "text": "175,600 (44)"}
{"id": "9d0ad8f8-3639-4f77-8749-00fd5f925e22", "page": 7, "type": "paragraph", "text": "300,140 (44)"}
{"id": "e943de2a-773d-4ce0-bf98-c527cec18cc5", "page": 7, "type": "paragraph", "text": "Female"}
{"id": "2ed52989-adfb-4d26-a094-61236ac71906", "page": 7, "type": "paragraph", "text": "154,860 (55)"}
{"id": "eaa7824e-034d-49d1-a6aa-b00d5b8d2eca", "page": 7, "type": "paragraph", "text": "220,252 (56)"}
{"id": "772200fc-e5e6-47f8-93b6-ca55bad307dc", "page": 7, "type": "paragraph", "text": "375,112 (56)"}
{"id": "cfa3d8fa-0166-4884-a48c-fc7407c7500e", "page": 7, "type": "paragraph", "text": "Race or ethnic group \u2014 no. (%)\u2020"}
{"id": "7dcb643d-3d98-4cee-a7c3-eb37b3ce1edc", "page": 7, "type": "paragraph", "text": "White"}
{"id": "b31eb033-cf2f-4092-b7fc-b6e33ffac0d8", "page": 7, "type": "paragraph", "text": "142,757 (51)"}
{"id": "1ef2038c-e3f2-4ac4-94a2-cf506be58dae", "page": 7, "type": "paragraph", "text": "198,434 (50)"}
{"id": "511a22e7-a21b-46cd-b564-0d86a352a304", "page": 7, "type": "paragraph", "text": "341,191 (51)"}
{"id": "ae4d2aef-e764-4e62-bb76-3883ebc29b06", "page": 7, "type": "paragraph", "text": "Black"}
{"id": "bfefc923-f01d-4adc-8638-1b393c47c790", "page": 7, "type": "paragraph", "text": "13,693 (5)"}
{"id": "3db19ec1-0295-4ccd-9555-71d3970bd124", "page": 7, "type": "paragraph", "text": "20,814 (5)"}
{"id": "7483d2a7-1ce4-4a39-9528-a15fd681e7fe", "page": 7, "type": "paragraph", "text": "34,507 (5)"}
{"id": "b79f47a2-a433-4d62-9aa9-6c950fd54322", "page": 7, "type": "paragraph", "text": "Asian"}
{"id": "ec4cdc51-799f-4cdf-a476-a8143871cce3", "page": 7, "type": "paragraph", "text": "58,416 (21)"}
{"id": "0bf81dd1-9502-472c-94e4-61a92a2757e9", "page": 7, "type": "paragraph", "text": "84,154 (21)"}
{"id": "31a03fa0-ee73-44b2-9006-0d0327101e57", "page": 7, "type": "paragraph", "text": "142,570 (21)"}
{"id": "6c63dd38-3f05-4871-b2cd-88fc2233db48", "page": 7, "type": "paragraph", "text": "Pacific Islander"}
{"id": "388aa1a9-7566-4311-8079-26d2860bfb81", "page": 7, "type": "paragraph", "text": "1,686 (1)"}
{"id": "2664e1ef-60fd-474f-8a4a-6eff7ae27ca3", "page": 7, "type": "paragraph", "text": "2,363 (1)"}
{"id": "2c760080-a98c-47a2-ab4e-7b800377b5e0", "page": 7, "type": "paragraph", "text": "4,049 (1)"}
{"id": "3246ced2-f98b-4f9e-a3a2-06c395a6a527", "page": 7, "type": "paragraph", "text": "Native American"}
{"id": "95d2c86a-d290-414c-8ef1-0fbd4dc640b1", "page": 7, "type": "paragraph", "text": "1,268 (<1)"}
{"id": "93d352b9-9e88-4249-ac77-1c04eba3f843", "page": 7, "type": "paragraph", "text": "1,836 (<1)"}
{"id": "d09e11f7-13f1-43c2-bc15-fba6dba371c9", "page": 7, "type": "paragraph", "text": "3,104 (<1)"}
{"id": "68fbaeab-10ef-495f-ab49-9720e1c5fa89", "page": 7, "type": "paragraph", "text": "Multiracial"}
{"id": "433ac3fd-1448-4fed-82ed-92edeab14a4e", "page": 7, "type": "paragraph", "text": "7,299 (3)"}
{"id": "5f0f9e40-c8b0-460d-b4c6-afb92df7c9db", "page": 7, "type": "paragraph", "text": "10,908 (3)"}
{"id": "549861ee-63fd-4098-9466-8223f505eb3e", "page": 7, "type": "paragraph", "text": "18,207 (3)"}
{"id": "c539e042-3b8e-4610-bd73-e6bc9cb4117f", "page": 7, "type": "paragraph", "text": "Unknown or other"}
{"id": "403d919b-138f-4cc9-85ee-d73fdc74fd9f", "page": 7, "type": "paragraph", "text": "54,281 (19)"}
{"id": "7b14b303-2fa6-482c-aab6-4b4ebc6778ce", "page": 7, "type": "paragraph", "text": "77,343 (20)"}
{"id": "1299fe38-60c6-4510-8989-8d04f022950a", "page": 7, "type": "paragraph", "text": "131,624 (19)"}
{"id": "b1e21710-4042-4c43-809e-1b955110b73f", "page": 7, "type": "paragraph", "text": "Hispanic ethnic group \u2014 no. (%)\u2020"}
{"id": "f99f94ae-895f-46f9-b3d5-e8967262e6de", "page": 7, "type": "paragraph", "text": "Yes"}
{"id": "d512d5fb-4196-4099-b0ec-fea21ee65164", "page": 7, "type": "paragraph", "text": "46,318 (17)"}
{"id": "ba3c16cf-4a6c-47b9-901e-54439de301b5", "page": 7, "type": "paragraph", "text": "65,868 (17)"}
{"id": "c3cf5156-ef63-457d-8cbe-29f91c148594", "page": 7, "type": "paragraph", "text": "112,186 (17)"}
{"id": "e0b32ac1-5b89-45a8-a30d-e674a3fae6bb", "page": 7, "type": "paragraph", "text": "No or unknown"}
{"id": "ac51e1fd-0487-4beb-a862-4f515f89a218", "page": 7, "type": "paragraph", "text": "233,082 (83)"}
{"id": "ff2a432c-f0a7-4504-b031-1fd013fa5971", "page": 7, "type": "paragraph", "text": "329,984 (83)"}
{"id": "e4dac627-5e4b-427b-a14a-db8449552a28", "page": 7, "type": "paragraph", "text": "563,066 (83)"}
{"id": "34cea0ba-bb96-4733-b543-e65e4f6135f0", "page": 7, "type": "paragraph", "text": "Coexisting illness \u2014 no. (%)"}
{"id": "b06062c8-1ac3-48e0-b1f9-7103396ef64c", "page": 7, "type": "paragraph", "text": "Asthma"}
{"id": "0c612480-54d7-4b04-b151-25ae3047a841", "page": 7, "type": "paragraph", "text": "39,909 (14)"}
{"id": "1a746979-b845-4f17-853f-ac3ff2225d36", "page": 7, "type": "paragraph", "text": "56,398 (14)"}
{"id": "2dafcc99-06c4-4540-9490-dd7021c311b6", "page": 7, "type": "paragraph", "text": "96,307 (14)"}
{"id": "c1d5384c-a1cd-43fa-a32e-94825cdf60b4", "page": 7, "type": "paragraph", "text": "Diabetes"}
{"id": "eef7bc3a-9639-43d5-bc70-7d76fa2e5323", "page": 7, "type": "paragraph", "text": "49,506 (18)"}
{"id": "c93cbd8c-9e3c-4447-9c0b-34ee47e82690", "page": 7, "type": "paragraph", "text": "69,924 (18)"}
{"id": "1b4aeca8-8b3e-4b2d-a680-d006757bb722", "page": 7, "type": "paragraph", "text": "119,430 (18)"}
{"id": "5bccc8b3-3a24-49cc-a2b7-d298180f14e0", "page": 7, "type": "paragraph", "text": "Chronic obstructive pulmonary disease"}
{"id": "e522eb1b-e0e8-49aa-9b0c-f85fd98dccf2", "page": 7, "type": "paragraph", "text": "5,628 (2)"}
{"id": "8e050adc-7d63-4721-83e0-d8dcfd68e122", "page": 7, "type": "paragraph", "text": "7,729 (2)"}
{"id": "d4be0cd1-f85a-44f4-94fc-ecba8b57a50b", "page": 7, "type": "paragraph", "text": "13,357 (2)"}
{"id": "8bb59bee-8def-4fa0-bf16-6aa1bf52033f", "page": 7, "type": "paragraph", "text": "Coronary heart disease"}
{"id": "a9a9ea0c-0052-4c52-ade3-0b708b14d8b9", "page": 7, "type": "paragraph", "text": "10,613 (4)"}
{"id": "f374cf68-a1b5-492f-b1d5-47421e2c8e0b", "page": 7, "type": "paragraph", "text": "14,883 (4)"}
{"id": "366149bb-dacf-4c7f-85cd-b6fca8a55d6b", "page": 7, "type": "paragraph", "text": "25,496 (4)"}
{"id": "115bed19-b674-4433-a1a5-f6a4e531d656", "page": 7, "type": "paragraph", "text": "Receipt of influenza vaccine in previous year"}
{"id": "92bc3723-47f4-4a50-91e8-a7009302de14", "page": 7, "type": "paragraph", "text": "Yes"}
{"id": "c3935a77-5e9b-4d58-9548-6ee112fc5d4c", "page": 7, "type": "paragraph", "text": "207,236 (74)"}
{"id": "33dba3b3-01c3-492f-abed-f43b64c3d3b2", "page": 7, "type": "paragraph", "text": "290,370 (73)"}
{"id": "9f96f3dd-18b2-4380-a55d-b45566ab773c", "page": 7, "type": "paragraph", "text": "497,606 (74)"}
{"id": "6ca82681-a1b4-44a9-9ba5-87866413a23a", "page": 7, "type": "paragraph", "text": "No"}
{"id": "4c9f48b3-b5bc-4a0d-8459-8ffca51fe4a1", "page": 7, "type": "paragraph", "text": "72,164 (26)"}
{"id": "bafa9cd4-2d18-4c33-ad0d-818dfc350243", "page": 7, "type": "paragraph", "text": "105,482 (27)"}
{"id": "1b13c180-9c70-4aca-8b47-4f719c534518", "page": 7, "type": "paragraph", "text": "177,646 (26)"}
{"id": "b7b729b3-1408-40d7-8c2d-f586543c9482", "page": 7, "type": "paragraph", "text": "* \u0007Additional details regarding the demographic and clinical characteristics of the participants in this age group, for those"}
{"id": "360ed5e2-85f8-47fd-b390-a29013798884", "page": 7, "type": "paragraph", "text": "in the younger age group (18 to 49 years), and for the entire study population (18 to 64 years of age) are provided in"}
{"id": "493fc145-23f0-4636-9cf0-b5eba60a1931", "page": 7, "type": "paragraph", "text": "Table S6 in the Supplementary Appendix."}
{"id": "a8b49c42-1ede-4deb-91bc-73975384550a", "page": 7, "type": "paragraph", "text": "\u2020 \u0007Race or ethnic group was reported by the participants."}
{"id": "dc53b72e-9db9-4bad-b28f-976418a80cc4", "page": 7, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "aab785dd-1628-4a9c-8963-f1aed8b65b74", "page": 7, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "24284afa-1bf6-4c46-a11d-15cf982ee46a", "page": 7, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "815d31d6-6943-4903-ab99-f92c30f16f49", "page": 8, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "f3b9ba83-6fd6-42f3-9248-ba2b9a5257cd", "page": 8, "type": "paragraph", "text": "2252"}
{"id": "9426c353-33e3-4938-9cad-154dbcb72f30", "page": 8, "type": "paragraph", "text": "The new engl and jour nal of medicine"}
{"id": "dcd474cc-99e7-4b49-86cb-763bfa6bbc18", "page": 8, "type": "paragraph", "text": "cine group as compared with 1510 participants"}
{"id": "b5447707-1466-4901-b3c1-98dd5f36fbcd", "page": 8, "type": "paragraph", "text": "(2.51 cases per 1000) in the standard-dose group"}
{"id": "6c6be411-ab56-48ff-85dd-1fa366ae345e", "page": 8, "type": "paragraph", "text": "(Table S8). For three exploratory objectives in this"}
{"id": "74ea9341-9bfb-49a1-9861-d756d4400b75", "page": 8, "type": "paragraph", "text": "age group, the relative vaccine effectiveness was"}
{"id": "ead821af-0afb-41dc-b46a-8addfd4faf94", "page": 8, "type": "paragraph", "text": "10.2% (95% CI, 1.4 to 18.2) against influenza A,"}
{"id": "a1114cbb-3123-417f-b92f-8c2d3a5076c1", "page": 8, "type": "paragraph", "text": "10.8% (95% CI, 6.6 to 14.7) against diagnosed"}
{"id": "e17e1067-c522-4b36-8149-9eef8a599d1e", "page": 8, "type": "paragraph", "text": "influenza, and 19.5% (95% CI, 5.4 to 31.5)"}
{"id": "839dfee0-9c34-4d65-9a72-c20af2179af4", "page": 8, "type": "paragraph", "text": "against influenza A in the subgroup with obe-"}
{"id": "e3118ccb-75a7-49ce-8adb-f760c32cb4f7", "page": 8, "type": "paragraph", "text": "sity (Tables S7 and S8)."}
{"id": "f01d0b17-1876-44fa-9c26-1b3865a3932c", "page": 8, "type": "paragraph", "text": "In the younger age group, the only explor-"}
{"id": "00cb13fe-a92e-4fc1-972f-240d25f8d308", "page": 8, "type": "paragraph", "text": "atory objective for which the relative vaccine ef-"}
{"id": "28d1978d-a5fc-453b-9bf3-17de36c29b66", "page": 8, "type": "paragraph", "text": "fectiveness was significantly below zero was"}
{"id": "05303d4c-8d2b-4f15-b944-f03ab44f3422", "page": 8, "type": "paragraph", "text": "death from any cause (\u221245.5; 95% CI, \u2212100.2 to"}
{"id": "d2b97b87-6f27-4721-9eda-102e2b0819d3", "page": 8, "type": "paragraph", "text": "\u22125.8) (Table S8). During the two influenza sea-"}
{"id": "01802e30-1304-4373-8844-b9161a0912cb", "page": 8, "type": "paragraph", "text": "sons, there were 145 deaths: 66 in the recombi-"}
{"id": "2ed91824-4957-4d9a-8223-ea83008b0fe7", "page": 8, "type": "paragraph", "text": "nant-vaccine group and 79 in the standard-dose"}
{"id": "727f7a07-0109-4e4a-b669-5c5e98243291", "page": 8, "type": "paragraph", "text": "group; most of these deaths occurred at least 61"}
{"id": "3aebe0cf-d415-485f-9fde-eb96bbcb419b", "page": 8, "type": "paragraph", "text": "days after vaccination. The most common causes"}
{"id": "3e0063a3-c26d-4ffd-89a4-59e6cf6d22ad", "page": 8, "type": "paragraph", "text": "of death in both study groups were cancer, ac-"}
{"id": "1756bfd9-84de-43f8-8c6f-c1f6b98c80e2", "page": 8, "type": "paragraph", "text": "cidents, homicide, suicide, and cardiovascular"}
{"id": "83381c67-932c-4d7e-b198-0899460aaa31", "page": 8, "type": "paragraph", "text": "events (Table S9). Causes of death as assessed by"}
{"id": "876656e0-76e9-4ccb-a5f4-d95e3ee7b134", "page": 8, "type": "paragraph", "text": "chart review were not considered by the investi-"}
{"id": "a8454510-0162-4d0a-9500-590f972c90a1", "page": 8, "type": "paragraph", "text": "gators to be related to either influenza or influ-"}
{"id": "de2d7f75-6e9e-4273-a432-51a353442dac", "page": 8, "type": "paragraph", "text": "enza vaccination."}
{"id": "9d34626c-5a7c-4179-96dd-4dca5760062e", "page": 8, "type": "paragraph", "text": "Single-season estimates of relative vaccine ef-"}
{"id": "688c216a-a064-41f2-a6f8-8cc893df6fce", "page": 8, "type": "paragraph", "text": "fectiveness were generally consistent with the"}
{"id": "ef88e9b5-e51a-467e-aefe-76d37e534fb2", "page": 8, "type": "paragraph", "text": "combined two-season estimates (Tables S10 and"}
{"id": "29596182-c010-4f1f-9faa-967be581096d", "page": 8, "type": "paragraph", "text": "S11). For the outcome of PCR-confirmed influ-"}
{"id": "6b422f27-ba38-4229-8c4d-d8f3283db593", "page": 8, "type": "paragraph", "text": "enza among patients in the older age group,"}
{"id": "a68a3c11-5d04-4998-8184-1d13451c0404", "page": 8, "type": "paragraph", "text": "relative vaccine effectiveness was 14.4% (95% CI,"}
{"id": "d2c86a7f-5233-41be-af4a-458bac4d75f7", "page": 8, "type": "paragraph", "text": "\u22121.1 to 27.5) during 2018\u20132019 and 16.1% (95%"}
{"id": "2bd9bded-8174-47b4-bb68-6b883d9efddc", "page": 8, "type": "paragraph", "text": "CI, 3.7 to 26.9) during 2019\u20132020."}
{"id": "7255a1dd-c245-423b-a2ac-4074a1d5fa38", "page": 8, "type": "paragraph", "text": "For both the PCR-confirmed influenza and"}
{"id": "4e91028c-e697-4aa2-b3bf-2c7addb0bc4e", "page": 8, "type": "paragraph", "text": "hospitalization outcomes, the results of sensitiv-"}
{"id": "496320bd-617a-4da9-8acc-4c242461efc7", "page": 8, "type": "paragraph", "text": "ity analyses were consistent with findings in the"}
{"id": "76621118-cb8e-40dd-8054-76622a027a92", "page": 8, "type": "paragraph", "text": "primary analyses (Tables S12 and S13). The esti-"}
{"id": "aad0009c-0d37-4c7d-99f7-8a18e3087d73", "page": 8, "type": "paragraph", "text": "mates of relative vaccine effectiveness from the"}
{"id": "99134999-09db-4b2d-a3e4-bd7cc862a2ac", "page": 8, "type": "paragraph", "text": "RSV-negative control analyses did not differ"}
{"id": "b208c249-323d-42fc-bd61-fb50460d91f8", "page": 8, "type": "paragraph", "text": "from zero (Table S14)."}
{"id": "023764ba-628e-41a0-9934-c5b3c12d1520", "page": 8, "type": "paragraph", "text": "Discussion"}
{"id": "254a30c8-6f8c-42e0-b220-03dd010886e9", "page": 8, "type": "paragraph", "text": "In this real-world study, we evaluated the effec-"}
{"id": "4f37d698-8cd5-4eac-985b-a707c3fbf8c3", "page": 8, "type": "paragraph", "text": "tiveness of a high-dose recombinant vaccine as"}
{"id": "d74b2ba2-bcee-4983-afe4-bdcb46c1d6ca", "page": 8, "type": "paragraph", "text": "compared with an egg-based standard-dose vac-"}
{"id": "89d6b2d0-d9f6-43e2-8095-4d116592b634", "page": 8, "type": "paragraph", "text": "cine among more than 1.6 million adults during"}
{"id": "2474243f-5be8-444f-ba89-9023634c61fe", "page": 8, "type": "paragraph", "text": "two influenza seasons. In our analysis of the"}
{"id": "a25a7856-b6df-4a6f-acdc-009dcb55cd9a", "page": 8, "type": "paragraph", "text": "primary outcome in older patients between 50"}
{"id": "b6eb4219-c273-49c4-84be-270ad4dc35d1", "page": 8, "type": "paragraph", "text": "and 64 years of age, the incidence of PCR-con-"}
{"id": "6da0b498-ec03-43b8-81ab-90b1fdebf016", "page": 8, "type": "paragraph", "text": "firmed influenza was 15.3% lower among those"}
{"id": "f4049099-b2aa-49a7-95c8-d04a70bd1de1", "page": 8, "type": "paragraph", "text": "who received the recombinant vaccine than"}
{"id": "f6b7bd2b-36db-4b11-9169-e27268962ce2", "page": 8, "type": "paragraph", "text": "among those who received a standard-dose vac-"}
{"id": "81af2fbd-e3f2-439d-9f8d-1d19ed4a489d", "page": 8, "type": "paragraph", "text": "cine, a finding that rejected the null hypothesis."}
{"id": "92afd4a8-35a0-48cd-bed1-b5380fa5df9c", "page": 8, "type": "paragraph", "text": "The evidence that the recombinant vaccine con-"}
{"id": "bb828a43-3fa2-4325-abd0-df1b7dacb62f", "page": 8, "type": "paragraph", "text": "Table 2. Primary and Secondary Outcomes and Relative Vaccine Effectiveness among Participants 50 to 64 Years of Age.*"}
{"id": "6b2be2b1-0b0f-4d16-a274-eb1c21310d41", "page": 8, "type": "paragraph", "text": "Outcome"}
{"id": "94100d1e-f446-413d-8e32-00eb797adfac", "page": 8, "type": "paragraph", "text": "Recombinant"}
{"id": "4e7d4fa8-e57f-4180-9ae2-f36e57c16bbc", "page": 8, "type": "paragraph", "text": "Vaccine"}
{"id": "1591465b-d57b-4e35-aad5-bb3f15482f17", "page": 8, "type": "paragraph", "text": "(N = 279,400)"}
{"id": "dac731b1-9dc1-48ec-b97a-939bd2ad2366", "page": 8, "type": "paragraph", "text": "Standard-Dose"}
{"id": "5c9fc70b-e503-45f3-a22e-4d073171ba81", "page": 8, "type": "paragraph", "text": "Vaccine"}
{"id": "34e17983-7852-4d7f-9b2e-25b5fe8cbc46", "page": 8, "type": "paragraph", "text": "(N = 395,852)"}
{"id": "1779ce23-ad74-4a14-a8d4-31bfddf485e8", "page": 8, "type": "paragraph", "text": "Unadjusted"}
{"id": "939a646b-ea4c-4f93-b265-c9daa3c5f873", "page": 8, "type": "paragraph", "text": "Rate Ratio"}
{"id": "a9824e30-9328-4aaf-b810-1a6203685000", "page": 8, "type": "paragraph", "text": "Adjusted"}
{"id": "23496a1e-72ef-4b2f-8513-d52dc99e493b", "page": 8, "type": "paragraph", "text": "Hazard Ratio"}
{"id": "a1211ee8-822c-49f3-9f42-0de41288730f", "page": 8, "type": "paragraph", "text": "(95% CI)\u2020"}
{"id": "33ed256b-42e1-43f3-9b67-757409b94536", "page": 8, "type": "paragraph", "text": "Relative Vaccine"}
{"id": "ba58bd4a-7d4c-4c34-b7d2-8d62739e7778", "page": 8, "type": "paragraph", "text": "Effectiveness"}
{"id": "bc5963f7-9e67-4c52-b326-d9cddf571fd8", "page": 8, "type": "paragraph", "text": "(95% CI)"}
{"id": "1c7eef33-1320-4ba8-bcf4-ca7bbaebf371", "page": 8, "type": "paragraph", "text": "P Value\u2021"}
{"id": "d275f840-9cdb-4c12-a37f-82547802a926", "page": 8, "type": "paragraph", "text": "no. of cases per 1000"}
{"id": "93412251-fe13-4f5d-bc48-da4c03149074", "page": 8, "type": "paragraph", "text": "%"}
{"id": "a4e8a85c-1e90-488b-8f6d-19ab2fc5d403", "page": 8, "type": "paragraph", "text": "Primary outcome"}
{"id": "b7508a8a-c3d4-434b-b5ab-29521d7c52e5", "page": 8, "type": "paragraph", "text": "PCR-confirmed influenza"}
{"id": "0d8b926f-133e-468b-9f95-7e2f4320acc2", "page": 8, "type": "paragraph", "text": "559 (2.00)"}
{"id": "8dc1aeca-3724-4ee3-942b-c94f183062c0", "page": 8, "type": "paragraph", "text": "925 (2.34)"}
{"id": "20ab34ac-62b7-4647-8c9b-ab0085f7ba8c", "page": 8, "type": "paragraph", "text": "0.86"}
{"id": "f3bb179c-8f53-4108-a9d2-fe1dcb8891a3", "page": 8, "type": "paragraph", "text": "0.85 (0.76 to 0.94)"}
{"id": "09dbf8ad-39cb-47d4-9c8c-57e90e0c9b1b", "page": 8, "type": "paragraph", "text": "15.3 (5.9 to 23.8)"}
{"id": "91769467-31f2-4bb4-a3a9-90d2bf286c5f", "page": 8, "type": "paragraph", "text": "0.002"}
{"id": "f56e5dfb-00ad-4d53-99f3-08e62063bf69", "page": 8, "type": "paragraph", "text": "Secondary outcomes"}
{"id": "7ebd0808-2010-49c6-a849-d6e3bf9c2529", "page": 8, "type": "paragraph", "text": "PCR-confirmed influenza A"}
{"id": "0b2e9cab-21c2-461f-be41-7de00e5d3184", "page": 8, "type": "paragraph", "text": "522 (1.87)"}
{"id": "30dcbc98-e684-480c-92cc-17f58cc8b344", "page": 8, "type": "paragraph", "text": "862 (2.18)"}
{"id": "f1698974-53a5-4c33-8065-e4f53ebc6b07", "page": 8, "type": "paragraph", "text": "0.86"}
{"id": "4847a294-aaea-4adf-9a68-5b170d8e5357", "page": 8, "type": "paragraph", "text": "0.84 (0.76 to 0.94)"}
{"id": "1e8b21a1-1005-4b09-8674-31575ce1544f", "page": 8, "type": "paragraph", "text": "15.7 (6.0 to 24.5)"}
{"id": "f44da6f5-46bd-429f-9a39-90a373b893ab", "page": 8, "type": "paragraph", "text": "0.002"}
{"id": "18ce3def-e170-4a27-af3c-0879b3327113", "page": 8, "type": "paragraph", "text": "PCR-confirmed influenza B"}
{"id": "2ced4ad3-3b10-44b6-b232-b81cc8df2d78", "page": 8, "type": "paragraph", "text": "37 (0.13)"}
{"id": "0ad561dc-1aca-417b-a1c4-cb713ac345fc", "page": 8, "type": "paragraph", "text": "64 (0.16)"}
{"id": "309397ac-88da-434d-b0a3-c72e8381f046", "page": 8, "type": "paragraph", "text": "0.82"}
{"id": "892625fe-c82e-4311-8710-61c11af48069", "page": 8, "type": "paragraph", "text": "0.90 (0.60 to 1.34)"}
{"id": "073a8b2d-79ee-47e1-93e1-fcbf14e56dbd", "page": 8, "type": "paragraph", "text": "10.3 (\u221233.9 to 39.9)"}
{"id": "f1fbb196-1c00-42d9-aabe-9d8dc1c976e5", "page": 8, "type": "paragraph", "text": "0.59"}
{"id": "7cc83b5c-019f-4eda-b8fc-2ab1d518397b", "page": 8, "type": "paragraph", "text": "Hospitalization for PCR-"}
{"id": "2cc2215e-1954-4a29-8fb4-ec5d2eb5ff39", "page": 8, "type": "paragraph", "text": "confirmed influenza"}
{"id": "10324ad0-8144-4776-b742-a6b44c9a2927", "page": 8, "type": "paragraph", "text": "95 (0.34)"}
{"id": "b7d2a271-e78d-4d67-acb3-68c553c5cee7", "page": 8, "type": "paragraph", "text": "153 (0.39)"}
{"id": "81855e86-e6fb-45a8-b88c-c47895d234c2", "page": 8, "type": "paragraph", "text": "0.88"}
{"id": "298467de-98ab-4784-8cf3-837852ceedaf", "page": 8, "type": "paragraph", "text": "0.84 (0.65 to 1.09)"}
{"id": "ae9ea1cd-c458-466c-8410-db8244644560", "page": 8, "type": "paragraph", "text": "15.9 (\u22129.2 to 35.2)"}
{"id": "3e190c85-09db-4a2f-9ca2-57797120d093", "page": 8, "type": "paragraph", "text": "0.19"}
{"id": "e5e2684b-9afd-4b24-a8a4-79a21e74a830", "page": 8, "type": "paragraph", "text": "Hospitalization for community-"}
{"id": "69c86c8f-0cc8-4973-ac9d-f7aa287895be", "page": 8, "type": "paragraph", "text": "acquired pneumonia"}
{"id": "e736c009-100f-4db3-a2b1-c4ff958f866c", "page": 8, "type": "paragraph", "text": "106 (0.38)"}
{"id": "1f147548-427e-47c1-bee3-338b2a169211", "page": 8, "type": "paragraph", "text": "183 (0.46)"}
{"id": "c8e44b0f-0672-4752-b4f1-41b11faa1329", "page": 8, "type": "paragraph", "text": "0.82"}
{"id": "27656346-fa13-4c28-b074-a12a11a4da83", "page": 8, "type": "paragraph", "text": "0.83 (0.66 to 1.06)"}
{"id": "c9e16e13-3c81-4526-8103-3971bd419f52", "page": 8, "type": "paragraph", "text": "16.7 (\u22125.6 to 34.4)"}
{"id": "f93a1576-84da-4ecb-bfec-e6ca5abe3044", "page": 8, "type": "paragraph", "text": "0.13"}
{"id": "a5c1d99b-1e61-47f1-a015-194ebed2fda7", "page": 8, "type": "paragraph", "text": "Hospitalization for cardiorespira-"}
{"id": "49443a93-4a77-438e-b239-d428dac3a15d", "page": 8, "type": "paragraph", "text": "tory event"}
{"id": "e7cca3e7-de9c-4295-b34b-1fb217184e93", "page": 8, "type": "paragraph", "text": "631 (2.26)"}
{"id": "403528fc-a629-496b-b35b-cbe9823a5cec", "page": 8, "type": "paragraph", "text": "890 (2.25)"}
{"id": "e7ca39de-47f3-4156-beb5-29b3c14076ce", "page": 8, "type": "paragraph", "text": "1.004"}
{"id": "60be90a6-6a26-41d7-938c-65424f8adb56", "page": 8, "type": "paragraph", "text": "0.98 (0.88 to 1.08)"}
{"id": "d6f426bb-b8d0-4e0f-9915-23051a2f30ae", "page": 8, "type": "paragraph", "text": "2.4 (\u22128.1 to 11.9)"}
{"id": "950660f2-bfe7-48e5-ab44-91c505211f47", "page": 8, "type": "paragraph", "text": "0.64"}
{"id": "9e70ce79-59be-401e-83e7-2d3b03458757", "page": 8, "type": "paragraph", "text": "* \u0007PCR denotes polymerase chain reaction."}
{"id": "6489476b-2898-4de6-981b-99891bff7072", "page": 8, "type": "paragraph", "text": "\u2020 \u0007Models were adjusted for age, age squared, sex, and race or ethnic group after weighting with stabilized facility-specific propensity scores."}
{"id": "12f40ff2-a1ff-4f6e-9d55-84b75256a321", "page": 8, "type": "paragraph", "text": "In post hoc sensitivity analyses, models were further adjusted for potential clustering according to facility and yielded results similar to"}
{"id": "13c2b2ca-679e-483d-b159-50060cffac5e", "page": 8, "type": "paragraph", "text": "those listed here. Details are provided in Table S13."}
{"id": "c3f3fd5c-1fe6-4668-87a5-dc32808370fd", "page": 8, "type": "paragraph", "text": "\u2021 \u0007Adjustment for multiplicity for the secondary outcomes was performed with the use of Holm\u2019s adjustment method. The P values that were"}
{"id": "ba6eb3f2-666f-497a-9463-0093c0572390", "page": 8, "type": "paragraph", "text": "obtained for the five secondary outcomes were rank-ordered and compared with corresponding adjusted nominal alpha values of 0.01, 0.0125,"}
{"id": "7d86127e-8b15-4ff9-9ea1-bb37558de000", "page": 8, "type": "paragraph", "text": "0.0167, 0.025, and 0.05."}
{"id": "e05968e4-676e-42d8-826f-061792fd29c8", "page": 8, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "91713813-23dd-4068-bb65-1757ae570319", "page": 8, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "cd13f52d-b411-43c4-8296-e577bf45575a", "page": 8, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "d859aeed-a0f4-481e-9e2a-0eafddee285a", "page": 9, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "62c802f2-ceb6-4f9f-944f-e1ba80989135", "page": 9, "type": "paragraph", "text": "2253"}
{"id": "9ad2d1ce-dd04-46fc-a128-61168d24c724", "page": 9, "type": "paragraph", "text": "Recombinant or Standard-Dose Influenza Vaccine"}
{"id": "273137b2-ad4f-4e55-b59a-8f6f4243b099", "page": 9, "type": "paragraph", "text": "ferred more protection against influenza than"}
{"id": "d3332e49-0611-4c22-8519-a51f254784cb", "page": 9, "type": "paragraph", "text": "standard-dose vaccines was strengthened by our"}
{"id": "94285bbb-2177-4415-aeed-b1132c8eff61", "page": 9, "type": "paragraph", "text": "cluster-randomized study design."}
{"id": "0733e84f-03ba-4f8b-9e05-111124ebe961", "page": 9, "type": "paragraph", "text": "In secondary analyses involving the same"}
{"id": "46ab35c6-9ee0-4126-9569-510b1bc2cb04", "page": 9, "type": "paragraph", "text": "older age group, the incidence of PCR-confirmed"}
{"id": "2315ed48-4b38-4fe9-9a93-2d94a06aa01b", "page": 9, "type": "paragraph", "text": "influenza A was 15.7% lower in the recombinant-"}
{"id": "07ec6f59-60ff-4bef-aa75-5c8220a9614f", "page": 9, "type": "paragraph", "text": "vaccine group than in the standard-dose group"}
{"id": "007fed9b-a414-4176-891a-404e09fabc2b", "page": 9, "type": "paragraph", "text": "(P = 0.002). Our analyses of the three additional"}
{"id": "42101a07-866e-4a97-b446-d58a2e811b65", "page": 9, "type": "paragraph", "text": "secondary outcomes in this age group suggested"}
{"id": "a49de09e-1f91-434d-829d-416af6dd3659", "page": 9, "type": "paragraph", "text": "that the recombinant vaccine may confer more"}
{"id": "5ee1e14b-4139-4718-83cf-c48908c333a0", "page": 9, "type": "paragraph", "text": "protection than standard-dose vaccines against"}
{"id": "1f04a34f-0a05-4a55-a56d-06aae42b0e81", "page": 9, "type": "paragraph", "text": "hospitalization outcomes. Although these find-"}
{"id": "f00e394d-2fa8-4295-9e26-feacfae38738", "page": 9, "type": "paragraph", "text": "ings were not significant, a post hoc analysis"}
{"id": "45fa4b94-bd77-4b85-a112-88d7ba5bef37", "page": 9, "type": "paragraph", "text": "combining hospitalization for PCR-confirmed"}
{"id": "262861f8-19a4-4d6e-9716-f07a8e7b6c65", "page": 9, "type": "paragraph", "text": "influenza and hospitalization for community-"}
{"id": "18679d6f-b5f4-45de-affd-8ad6d4b0b9ae", "page": 9, "type": "paragraph", "text": "acquired pneumonia yielded a relative vaccine"}
{"id": "8922ea5a-9051-4883-afd1-98099acf068e", "page": 9, "type": "paragraph", "text": "effectiveness of 19.7% (95% CI, 2.8 to 33.7)."}
{"id": "e6445a1f-2fb7-413a-84c7-2691e8946459", "page": 9, "type": "paragraph", "text": "The 12 exploratory analyses yielded some-"}
{"id": "07acbb1d-1f94-415b-bf7a-14fb321dc804", "page": 9, "type": "paragraph", "text": "what inconsistent results. For influenza diagno-"}
{"id": "a1ae710a-e1c9-43ed-a507-501b9d247180", "page": 9, "type": "paragraph", "text": "ses overall (including unconfirmed diagnoses)"}
{"id": "df881b56-3d09-4805-8461-27a78044842b", "page": 9, "type": "paragraph", "text": "among patients between the ages of 18 and 49"}
{"id": "edd6cc15-270a-4873-9c43-9fa679c2aec7", "page": 9, "type": "paragraph", "text": "years, the incidence was lower in the recombi-"}
{"id": "d88b6e28-170d-4e0f-b07d-3789f2963687", "page": 9, "type": "paragraph", "text": "nant-vaccine group than in the standard-dose"}
{"id": "38bc8e1f-e1eb-4dda-9f3a-b48132d421af", "page": 9, "type": "paragraph", "text": "group (relative vaccine effectiveness, 10.8%; 95%"}
{"id": "23a64e81-bcff-4ce9-a25a-3942a85d5221", "page": 9, "type": "paragraph", "text": "CI, 6.6 to 14.7). For PCR-confirmed influenza A,"}
{"id": "6c3924c6-ba3c-4976-b37f-b015f3accf97", "page": 9, "type": "paragraph", "text": "the incidence was similarly lower in the recom-"}
{"id": "9d28b9c9-6fc1-49a2-89ec-61e7f93c3ce9", "page": 9, "type": "paragraph", "text": "binant-vaccine group (relative vaccine effective-"}
{"id": "18d38569-4cf2-4abd-a9ce-88357f9f2529", "page": 9, "type": "paragraph", "text": "ness, 10.2; 95% CI, 1.4 to 18.2). For 5 of the"}
{"id": "3ceef97e-2bd0-4575-85af-e087230b688d", "page": 9, "type": "paragraph", "text": "other 10 exploratory analyses (2 of which were"}
{"id": "293cebed-5e55-4c6b-863c-6909f21dba8f", "page": 9, "type": "paragraph", "text": "performed in participants between 50 and 64"}
{"id": "f832a3ba-972d-479b-ab79-3cc3e469b6fa", "page": 9, "type": "paragraph", "text": "years of age), the estimated relative vaccine ef-"}
{"id": "b231329f-59b9-4dcc-8573-723819ed24c3", "page": 9, "type": "paragraph", "text": "fectiveness was in the range of 1 to 10% with"}
{"id": "c5deef7e-2abb-4dee-a0be-2073ae80e9dc", "page": 9, "type": "paragraph", "text": "95% confidence intervals overlapping 0%. The"}
{"id": "93c5c07b-fbb2-4923-979e-037c3a601c3b", "page": 9, "type": "paragraph", "text": "remaining 5 exploratory analyses (1 of which"}
{"id": "73aceb9f-b463-420e-979f-5a9bb6dbdc5e", "page": 9, "type": "paragraph", "text": "was performed in participants between 50 and"}
{"id": "2cdf17cf-fe48-470f-8104-dffb1371bd15", "page": 9, "type": "paragraph", "text": "64 years of age) yielded negative estimates for"}
{"id": "779d842f-bc56-44cf-b44a-0d2df49a2e45", "page": 9, "type": "paragraph", "text": "relative vaccine effectiveness, including the anal-"}
{"id": "0d97fd05-d6fb-4f67-ba34-036ac2b23b42", "page": 9, "type": "paragraph", "text": "ysis of death from any cause among participants"}
{"id": "d9a1b3e6-dcaf-4fc5-b3f9-bbd4b03a20f7", "page": 9, "type": "paragraph", "text": "between 18 and 49 years of age (relative vaccine"}
{"id": "d4ae7131-042e-4dc3-8642-9847e3184a17", "page": 9, "type": "paragraph", "text": "effectiveness, \u221245.5; 95% CI, \u2212100.2 to \u22125.8)."}
{"id": "bbc1289e-edff-4c73-91e8-21bb454c87e6", "page": 9, "type": "paragraph", "text": "Chart reviews of all 145 deaths in this age group"}
{"id": "5ba95cc3-f8a0-4a19-8e8d-853cf5a9bc5b", "page": 9, "type": "paragraph", "text": "did not suggest that the recombinant vaccine"}
{"id": "205e300a-501f-4a60-b3e7-25dba7224674", "page": 9, "type": "paragraph", "text": "caused any deaths or that standard-dose vaccines"}
{"id": "2aa94ff9-d734-4ff1-9bda-21bf356da489", "page": 9, "type": "paragraph", "text": "prevented more deaths than the recombinant"}
{"id": "74a97e16-7d12-492a-a012-1441cf93bf12", "page": 9, "type": "paragraph", "text": "Figure 3. Subgroup Analysis of Relative Vaccine Effectiveness against Influenza among Participants between 50"}
{"id": "3b569fe6-1e82-466b-9f19-30022267b680", "page": 9, "type": "paragraph", "text": "and 64 Years of Age, According to Preexisting Conditions."}
{"id": "81196436-d32d-426b-b5f6-f594d7d70b35", "page": 9, "type": "paragraph", "text": "Shown is a forest plot of the relative effectiveness of the recombinant vaccine as compared with a standard-dose"}
{"id": "0a978982-1e02-4e10-ae7a-74bc89310735", "page": 9, "type": "paragraph", "text": "vaccine against influenza as confirmed by polymerase-chain-reaction (PCR) assay, hospitalization for PCR-confirmed"}
{"id": "eb3fa3bb-694f-4918-a725-01217609abf4", "page": 9, "type": "paragraph", "text": "influenza, and hospitalization for community-acquired pneumonia among study participants in the older age group,"}
{"id": "11dbad4d-246d-4083-aa13-df2d0aee7d62", "page": 9, "type": "paragraph", "text": "according to the presence of five prespecified preexisting conditions."}
{"id": "8d75df52-f64b-401d-9aec-3813c10f3877", "page": 9, "type": "paragraph", "text": "\u221210"}
{"id": "e15fa52d-4bf0-4677-bedc-4613141cf137", "page": 9, "type": "paragraph", "text": "0"}
{"id": "67ab3421-b847-4372-9964-2a1a4856ad33", "page": 9, "type": "paragraph", "text": "10"}
{"id": "63953da2-24c8-4677-9f14-2b14d5c19ed8", "page": 9, "type": "paragraph", "text": "20"}
{"id": "289b51c4-7adf-450f-a37c-bf70cf450469", "page": 9, "type": "paragraph", "text": "\u221220"}
{"id": "ff0c8d08-f156-486b-8d3c-813a47d7254e", "page": 9, "type": "paragraph", "text": "15"}
{"id": "8a15d329-164d-4983-87cf-665bbae546c0", "page": 9, "type": "paragraph", "text": "\u221215"}
{"id": "65fd4134-77c5-41b8-8d43-82bde27caf67", "page": 9, "type": "paragraph", "text": "5"}
{"id": "6edc4871-c4ec-4591-909d-e0a878c5393d", "page": 9, "type": "paragraph", "text": "\u22125"}
{"id": "d7cda157-d7b8-4b14-94a1-d239de5408dc", "page": 9, "type": "paragraph", "text": "25"}
{"id": "2a6bedc1-acea-4b04-97a4-c38d52a770ee", "page": 9, "type": "paragraph", "text": "\u221225"}
{"id": "68c15600-079b-4559-853e-e569fa3ebcac", "page": 9, "type": "paragraph", "text": "40"}
{"id": "3f6ee25e-0d46-4277-9359-b2a902aa9fac", "page": 9, "type": "paragraph", "text": "\u221240"}
{"id": "981d4f88-2dba-4207-84b9-3f8dacba7d20", "page": 9, "type": "paragraph", "text": "35"}
{"id": "efa5f12f-0fa7-4975-94f0-5715649379f6", "page": 9, "type": "paragraph", "text": "\u221235"}
{"id": "06266183-9bfd-4607-8cad-ec5893eb25f6", "page": 9, "type": "paragraph", "text": "45"}
{"id": "f7398f25-d53f-49e8-87a4-ff5daaccb3ed", "page": 9, "type": "paragraph", "text": "\u221245"}
{"id": "835bb7bb-a36d-4a20-8846-6e8b61cc7040", "page": 9, "type": "paragraph", "text": "30"}
{"id": "16612faa-b129-4afc-9c3d-dba8b8198812", "page": 9, "type": "paragraph", "text": "55"}
{"id": "41e516f9-1500-4fcc-9d3e-69df7b9b13e1", "page": 9, "type": "paragraph", "text": "50"}
{"id": "6e8f72a3-6bf5-4649-81ec-b746a1d1b497", "page": 9, "type": "paragraph", "text": "PCR-confirmed influenza"}
{"id": "e6411e42-4cc3-4396-bb38-c5ee216a2bbc", "page": 9, "type": "paragraph", "text": "Cardiovascular disease"}
{"id": "f68ffc74-149a-4603-aa2e-87423b50d25b", "page": 9, "type": "paragraph", "text": "Respiratory disease"}
{"id": "644f399a-6331-469a-a1a7-3bdf54ee1fb0", "page": 9, "type": "paragraph", "text": "Cardiorespiratory disease"}
{"id": "449418df-e6f5-4c23-bd7d-cdd975aead71", "page": 9, "type": "paragraph", "text": "Obesity"}
{"id": "64508a65-665a-4d50-8593-774b60fb30a8", "page": 9, "type": "paragraph", "text": "Diabetes"}
{"id": "045a0b67-5f05-42b4-a41b-2f3b6276b6ae", "page": 9, "type": "paragraph", "text": "Any of the above conditions"}
{"id": "e05bdf63-1235-4edf-8a1e-09001cbc0256", "page": 9, "type": "paragraph", "text": "Hospitalization for PCR-confirmed influenza"}
{"id": "599bc21e-4ed5-47b0-8ec8-0edc49bb3360", "page": 9, "type": "paragraph", "text": "Cardiovascular disease"}
{"id": "f59d04ba-b518-4a7a-8148-18cc7f67ba14", "page": 9, "type": "paragraph", "text": "Respiratory disease"}
{"id": "579ff9ac-970a-4282-8f91-9ae1a706e72f", "page": 9, "type": "paragraph", "text": "Cardiorespiratory disease"}
{"id": "10a71f27-a559-4c7d-bef2-7c6090ca0960", "page": 9, "type": "paragraph", "text": "Obesity"}
{"id": "f14e0de7-fcd8-4358-9f72-30a699615d12", "page": 9, "type": "paragraph", "text": "Diabetes"}
{"id": "e5811183-4dbe-4e83-ba3c-38ebfc309663", "page": 9, "type": "paragraph", "text": "Any of the above conditions"}
{"id": "628f4adb-5811-4d67-ab96-9d1515382fd2", "page": 9, "type": "paragraph", "text": "Hospitalization for community-acquired pneumonia"}
{"id": "cf1de070-2824-4081-b76a-f0afbf76ae1c", "page": 9, "type": "paragraph", "text": "Cardiovascular disease"}
{"id": "fc25947e-8254-4937-ba86-00e174a1f423", "page": 9, "type": "paragraph", "text": "Respiratory disease"}
{"id": "f1c77e69-c52d-4466-96fc-07d35ad46b7d", "page": 9, "type": "paragraph", "text": "Cardiorespiratory disease"}
{"id": "e91847f7-3177-4e76-bc84-6a75c7822408", "page": 9, "type": "paragraph", "text": "Obesity"}
{"id": "18dcdd75-2f21-4dec-9251-4411df4dd96d", "page": 9, "type": "paragraph", "text": "Diabetes"}
{"id": "a1ac6a57-ad83-4004-bb3a-313e7dd5a457", "page": 9, "type": "paragraph", "text": "Any of the above conditions"}
{"id": "2fdb7c6b-40e8-41d1-8978-770d4712bc79", "page": 9, "type": "paragraph", "text": "Relative Vaccine Effectiveness (95% CI)"}
{"id": "e64797f1-e7ed-472d-b86f-93775c73fa13", "page": 9, "type": "paragraph", "text": "Percentage"}
{"id": "84c3c681-3f8d-4db2-acd5-7aa5f99c8d46", "page": 9, "type": "paragraph", "text": "Subgroup"}
{"id": "35f37f1d-69b1-4987-bc08-9e4a541715fd", "page": 9, "type": "paragraph", "text": "\u221230"}
{"id": "e8bc2741-1774-4229-91a3-d95a7f26daed", "page": 9, "type": "paragraph", "text": "\u221250"}
{"id": "77f1d376-c2e0-4d3b-ad6c-39761b18083c", "page": 9, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "91f2f849-2efb-4e1e-95a2-d66f02e26f2e", "page": 9, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "bbb76bf8-4cf8-4779-bb11-725d489a2a4b", "page": 9, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "c1cc6bb6-64d0-4463-a15e-86ee3ebdaf8c", "page": 10, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "cc6f3a00-95ef-4c1c-b89b-aee8373ad451", "page": 10, "type": "paragraph", "text": "2254"}
{"id": "4bfcb4db-640a-4141-b705-854539b0ad88", "page": 10, "type": "paragraph", "text": "The new engl and jour nal of medicine"}
{"id": "3f47460b-0897-439c-9365-e316b6bfc6c5", "page": 10, "type": "paragraph", "text": "vaccine. Mortality in both groups of vaccinees"}
{"id": "9670e61d-e8b0-4f08-9ca1-5b9c452fac32", "page": 10, "type": "paragraph", "text": "was substantially lower than population-wide"}
{"id": "89e25c96-40b5-4fc9-9df0-12eb21a06b1f", "page": 10, "type": "paragraph", "text": "mortality at KPNC and nationwide in a similar"}
{"id": "028d0315-5ebd-4d59-a90e-e3f1ec73befa", "page": 10, "type": "paragraph", "text": "age group.11,12"}
{"id": "29d151be-f0be-4b7f-957d-9937d1106577", "page": 10, "type": "paragraph", "text": "If standard-dose vaccines were already pre-"}
{"id": "74b24866-0148-47a9-992a-d916a393ca9d", "page": 10, "type": "paragraph", "text": "venting most cases of influenza and break-"}
{"id": "58d8022e-e302-4b19-a4b0-6daee2aba1fa", "page": 10, "type": "paragraph", "text": "through cases were uncommon, preventing 15%"}
{"id": "6c89611b-7ab5-4605-a102-7c1b797d1d08", "page": 10, "type": "paragraph", "text": "of breakthrough cases would be of modest pub-"}
{"id": "15aae823-ecb4-4c37-82df-e089b707a886", "page": 10, "type": "paragraph", "text": "lic health benefit. However, since standard-dose"}
{"id": "38083895-4cf7-4b8f-9773-b14876173e2f", "page": 10, "type": "paragraph", "text": "vaccines prevent at most 40 to 60% of influenza"}
{"id": "842b6f56-d4df-4ad3-a885-57957747fd8b", "page": 10, "type": "paragraph", "text": "cases annually,13 reducing the incidence of break-"}
{"id": "fdb944f9-5c8b-4a9b-9b5e-5adc4e01fb0f", "page": 10, "type": "paragraph", "text": "through influenza by 15% would provide a sub-"}
{"id": "2bcbcfd2-d296-4895-8e21-4ec56c51c8c7", "page": 10, "type": "paragraph", "text": "stantial public health benefit, especially during"}
{"id": "482f6424-1e59-4b93-93d1-92672868475d", "page": 10, "type": "paragraph", "text": "more severe influenza seasons."}
{"id": "503a07ab-d833-4998-8b46-1b08bb1bf622", "page": 10, "type": "paragraph", "text": "Several studies have shown benefit for the"}
{"id": "df302d16-989a-43da-9ce7-5e6bce3041c7", "page": 10, "type": "paragraph", "text": "recombinant vaccine and other high-dose influ-"}
{"id": "223ee402-af20-4740-8073-da52608e7d8a", "page": 10, "type": "paragraph", "text": "enza vaccines as compared with standard-dose"}
{"id": "5156a4d9-62bb-45a9-aadd-736633e1b991", "page": 10, "type": "paragraph", "text": "vaccines in adults who are 65 years of age or"}
{"id": "ebddc947-b78c-4bea-8317-9bc5cf4ab5e3", "page": 10, "type": "paragraph", "text": "older, findings that have been attributed to an"}
{"id": "eb9632ed-f186-485f-b80c-9d3fc951de97", "page": 10, "type": "paragraph", "text": "improved immune response.5,14-17 In the current"}
{"id": "c973173a-9508-4325-a9c4-da233a4355d0", "page": 10, "type": "paragraph", "text": "study, we compared the effectiveness of the"}
{"id": "c37a1ded-ad98-406c-b68d-e16b3f2fa76c", "page": 10, "type": "paragraph", "text": "high-dose recombinant vaccine with that of"}
{"id": "f0b11500-9845-4c54-883f-b39d3e392cb9", "page": 10, "type": "paragraph", "text": "standard-dose vaccines in patients between the"}
{"id": "8d413717-ad28-4d8b-9e23-aa4dd4f6600f", "page": 10, "type": "paragraph", "text": "ages of 18 and 64 years. The effectiveness of"}
{"id": "02e1ae12-ff70-4e39-8e4f-8471793fef9d", "page": 10, "type": "paragraph", "text": "standard-dose vaccines \u2014 especially against the"}
{"id": "25e828c5-92e2-4e16-8fd0-7a2b234a50b1", "page": 10, "type": "paragraph", "text": "influenza A H3N2 subtype \u2014 may be attenuated"}
{"id": "263bc37e-8301-4e67-b658-53133d35384f", "page": 10, "type": "paragraph", "text": "by antigenic drift during egg-based manufactur-"}
{"id": "4328082c-2a2c-43af-92ef-a41367c9b313", "page": 10, "type": "paragraph", "text": "ing, whereas the recombinant vaccine is not"}
{"id": "1fba5be3-ebc8-4ca1-865b-772d68d11c8b", "page": 10, "type": "paragraph", "text": "susceptible to such drift. However, data from the"}
{"id": "c25312ca-957c-4710-a37f-34134db0d51f", "page": 10, "type": "paragraph", "text": "California Department of Public Health showed"}
{"id": "818c39c6-085b-42b0-9eef-283a3c4191da", "page": 10, "type": "paragraph", "text": "that the H3N2 strain circulated only during the"}
{"id": "f24bff8d-6f7b-49c6-8843-5be941f6dbc3", "page": 10, "type": "paragraph", "text": "second half of the 2018\u20132019 season,18 and even"}
{"id": "97db6c60-71e2-4d8d-98b5-40944308ff9b", "page": 10, "type": "paragraph", "text": "then, the circulating strain had drifted such that"}
{"id": "2a4ecf60-d54b-4869-9d0a-6b0eb275099e", "page": 10, "type": "paragraph", "text": "it was poorly matched to both the recombinant"}
{"id": "c099496d-876d-447b-8af6-20b64d1efa35", "page": 10, "type": "paragraph", "text": "vaccine and the standard-dose vaccines.19,20 Dur-"}
{"id": "764a2d76-91ea-473b-bbbc-6dc2188d50b3", "page": 10, "type": "paragraph", "text": "ing our study period, the observed benefit of the"}
{"id": "04209553-c94f-44e3-86ea-7a1a7ac22c03", "page": 10, "type": "paragraph", "text": "recombinant vaccine as compared with a stan-"}
{"id": "dd73d398-ddd7-4da1-9282-578f04514f08", "page": 10, "type": "paragraph", "text": "dard-dose vaccine seems less likely due to higher"}
{"id": "27d5220b-7d95-48c6-baa7-618f42b44449", "page": 10, "type": "paragraph", "text": "relative vaccine effectiveness against H3N2 than"}
{"id": "e0f5cfbb-8412-4ad0-8521-329777c8103a", "page": 10, "type": "paragraph", "text": "to higher effectiveness against influenza A over-"}
{"id": "4fa637a4-9c40-4332-adb1-fa28c72306e0", "page": 10, "type": "paragraph", "text": "all associated with its higher dose of hemagglu-"}
{"id": "5ad918ad-9553-4e70-ab3c-5df068a60dba", "page": 10, "type": "paragraph", "text": "tinin antigen."}
{"id": "54a1e61a-6b74-4159-a101-7dcbdbc1ac15", "page": 10, "type": "paragraph", "text": "A strength of our study is that the two study"}
{"id": "fc3e5591-a861-4f85-8242-4a3a8bf2aae4", "page": 10, "type": "paragraph", "text": "vaccine formulations were alternated in weekly"}
{"id": "a71d9dfa-11f5-4319-add6-f7780e7fa93d", "page": 10, "type": "paragraph", "text": "intervals of time at each facility, which allowed"}
{"id": "0527d2c9-81a9-4642-b5ef-0243e32c5d79", "page": 10, "type": "paragraph", "text": "us to balance covariates of interest as designed."}
{"id": "bd4655a0-d776-45fd-99eb-055288f264a1", "page": 10, "type": "paragraph", "text": "In every KPNC geographic area, when influenza"}
{"id": "61d2eec8-958e-4c41-bdf2-8dde9b92870e", "page": 10, "type": "paragraph", "text": "arrived, there were already participants who had"}
{"id": "94fb5322-7152-490b-9469-30bab93fb65f", "page": 10, "type": "paragraph", "text": "received one of the two formulations of vaccine"}
{"id": "02bf7ecd-a6fa-40a3-9d2e-96735d9455ed", "page": 10, "type": "paragraph", "text": "and who were similar with respect to demo-"}
{"id": "28a140e9-6d79-4dc6-a717-99691bfd3f71", "page": 10, "type": "paragraph", "text": "graphic characteristics, coexisting illnesses,"}
{"id": "6b4b8dc0-9a5d-47a0-8ed0-895218bbe156", "page": 10, "type": "paragraph", "text": "health care\u2013seeking behavior, and the number"}
{"id": "bcb30c28-4767-4c6f-8ba8-aefa22342575", "page": 10, "type": "paragraph", "text": "of weeks since vaccination. To our knowledge,"}
{"id": "185068d2-ee1c-4f1c-be7b-786104f8bac4", "page": 10, "type": "paragraph", "text": "this design has not been previously used, and its"}
{"id": "4b0d1c2d-b278-474d-9165-6b6f18aa95b5", "page": 10, "type": "paragraph", "text": "handling of potential confounding bias has not"}
{"id": "6b0c6d71-30be-4476-9c52-75a7ee41ddb5", "page": 10, "type": "paragraph", "text": "been formally studied. Our intent was to mini-"}
{"id": "4fe90ea2-7723-4a0f-89ba-454890e809fc", "page": 10, "type": "paragraph", "text": "mize imbalances between the participants who"}
{"id": "75390086-98fe-47ff-8495-8c92cb9c1737", "page": 10, "type": "paragraph", "text": "received each vaccine, both within and between"}
{"id": "c7bee090-1a08-46b8-9b1e-3ed3646c615d", "page": 10, "type": "paragraph", "text": "facilities. We also included several sensitivity"}
{"id": "d95725c8-38ec-42a8-ac60-05e2c6c448ec", "page": 10, "type": "paragraph", "text": "analyses to address potential biases from clus-"}
{"id": "e81b6bec-365a-4570-9381-2e751402cf51", "page": 10, "type": "paragraph", "text": "tering according to facility. Sensitivity analyses"}
{"id": "de0832c0-1365-4220-85f1-2bb4117c2434", "page": 10, "type": "paragraph", "text": "that were stratified either according to facility"}
{"id": "ea611a96-a373-4e75-a52c-7ed1199eb533", "page": 10, "type": "paragraph", "text": "(to compare within facilities) or according to"}
{"id": "7effe9bb-cb3d-42a9-bacc-e72521756f58", "page": 10, "type": "paragraph", "text": "week (to compare between facilities) showed a"}
{"id": "42fe46f7-b9bb-4dc9-b3ea-3112176ed08d", "page": 10, "type": "paragraph", "text": "relative vaccine effectiveness of approximately"}
{"id": "0da70e29-f53b-4631-9603-d65c7610466c", "page": 10, "type": "paragraph", "text": "15%, similar to the findings of our primary"}
{"id": "9c1b1fc1-ef1d-4fbe-9583-bb84835e727d", "page": 10, "type": "paragraph", "text": "analysis."}
{"id": "477f77ad-f46a-409b-8ccf-b8661923e20f", "page": 10, "type": "paragraph", "text": "Our study also has several limitations. First,"}
{"id": "b782fea6-aef5-47df-8183-bc85d91640d4", "page": 10, "type": "paragraph", "text": "in our real-world setting, compliance with the"}
{"id": "dc231295-70ee-4a37-8990-0d127ac87934", "page": 10, "type": "paragraph", "text": "weekly assigned vaccine schedule occasionally"}
{"id": "1c93ca09-e9b3-4ad7-a02c-080bd0ffdf16", "page": 10, "type": "paragraph", "text": "varied because of logistic constraints, including"}
{"id": "746c7859-571e-45a6-af19-a88e889d4455", "page": 10, "type": "paragraph", "text": "supply-chain issues for the recombinant vaccine,"}
{"id": "7d3a4dc0-837e-4a56-9bda-42cb5149d552", "page": 10, "type": "paragraph", "text": "which led to different numbers of participants in"}
{"id": "732ad858-0e42-486d-890d-ff03efb541eb", "page": 10, "type": "paragraph", "text": "the two groups. Second, our data were limited to"}
{"id": "457e9d80-0f78-492d-82fb-3073268e4928", "page": 10, "type": "paragraph", "text": "two influenza seasons; relative vaccine effective-"}
{"id": "eacd18fd-622f-463f-938d-ae00f112020e", "page": 10, "type": "paragraph", "text": "ness may vary across seasons, depending on the"}
{"id": "bd786691-444a-4f84-9a7e-6661423e744b", "page": 10, "type": "paragraph", "text": "vaccine match with circulating strains. Third,"}
{"id": "7f3dcddf-6a22-455f-9a59-e09a4ae43a7f", "page": 10, "type": "paragraph", "text": "our primary outcome did not include infections"}
{"id": "a028421c-0f67-4d08-be5e-61e9ba2375ea", "page": 10, "type": "paragraph", "text": "in persons who did not undergo PCR testing,"}
{"id": "fe716ecc-60be-4964-8ed8-d8f7ac368e1a", "page": 10, "type": "paragraph", "text": "which limits its generalizability. Fourth, the study"}
{"id": "21f9ebca-1d82-48e7-8005-0ccf2c54df27", "page": 10, "type": "paragraph", "text": "had limited power to detect a clinically mean-"}
{"id": "7cdc05ea-5c73-47cb-8dfd-809a6f3f2702", "page": 10, "type": "paragraph", "text": "ingful benefit of the recombinant vaccine as"}
{"id": "72e6566e-0049-4819-ac81-4e20a088e2be", "page": 10, "type": "paragraph", "text": "compared with a standard-dose vaccine with"}
{"id": "f8acd7ec-5899-4d10-b0f6-6ff59ea2c0ea", "page": 10, "type": "paragraph", "text": "respect to less frequent outcomes, such as hos-"}
{"id": "1821135d-c678-41be-a009-a8dae0191e4d", "page": 10, "type": "paragraph", "text": "pitalization for PCR-confirmed influenza. Finally,"}
{"id": "14d32390-245a-4c16-a26c-e79cf692445c", "page": 10, "type": "paragraph", "text": "although KPNC has a diverse population, it may"}
{"id": "9d3c881a-a959-4771-a121-83afc1b84fa5", "page": 10, "type": "paragraph", "text": "not be representative of other populations in the"}
{"id": "7efa4e92-6013-499d-95ce-c567bcb1096b", "page": 10, "type": "paragraph", "text": "United States."}
{"id": "b3899ebf-8746-4303-b5cf-bd40cfe19669", "page": 10, "type": "paragraph", "text": "In this study performed during two influenza"}
{"id": "c9876b02-6cd3-4a8e-b73f-a8f88c2cce85", "page": 10, "type": "paragraph", "text": "seasons, participants between the ages of 50 and"}
{"id": "1efd96f4-35b8-457f-9444-1d29407865df", "page": 10, "type": "paragraph", "text": "64 years who received the recombinant vaccine"}
{"id": "7b318a7c-cc12-4adb-91a2-8fa977c1f0f4", "page": 10, "type": "paragraph", "text": "had more protection against confirmed influenza"}
{"id": "c6ee2ce8-495e-4369-8bbb-264ebf46e2c8", "page": 10, "type": "paragraph", "text": "than those who received a standard-dose vaccine."}
{"id": "54766781-d378-47ae-89af-e9b458c332cc", "page": 10, "type": "paragraph", "text": "Supported by Sanofi."}
{"id": "e74f2f48-aae9-4045-8ff0-3c28a1ee3f04", "page": 10, "type": "paragraph", "text": "Disclosure forms provided by the authors are available with"}
{"id": "92f64364-18f2-4ab6-8a2c-887e5ad3e3a7", "page": 10, "type": "paragraph", "text": "the full text of this article at NEJM.org."}
{"id": "31675d4f-14a8-454c-8c01-0fbb219feb48", "page": 10, "type": "paragraph", "text": "We thank many groups within Kaiser Permanente Northern"}
{"id": "958c8c6c-e2df-40a8-a5dd-621beb8e1dec", "page": 10, "type": "paragraph", "text": "California for their dedication and contributions to this study,"}
{"id": "ea9d5fda-6187-4ed4-9fb2-af27890a36fb", "page": 10, "type": "paragraph", "text": "including the members of the KPNC Seasonal Flu Program, the"}
{"id": "d6f9b1d9-c663-4bcc-931d-d36737ef585f", "page": 10, "type": "paragraph", "text": "clinical teams who managed and administered influenza vac-"}
{"id": "f23e296b-0759-40aa-b8d9-156b13bceba2", "page": 10, "type": "paragraph", "text": "cines, the pharmacy teams, and the KPNC regional laboratory,"}
{"id": "aa0ac306-4f44-48bb-94ce-34109de95e82", "page": 10, "type": "paragraph", "text": "without whose support this study would not have been possible;"}
{"id": "bd51d222-c94b-45ba-9354-a2f5f807d098", "page": 10, "type": "paragraph", "text": "and Ruvim Izikson of Sanofi for scientific discussions and co-"}
{"id": "013fb213-62b5-432e-a062-183bb7702f77", "page": 10, "type": "paragraph", "text": "ordination."}
{"id": "5a99ee86-fa83-4588-b372-f2358010819b", "page": 10, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "69a97afd-9cb9-42bc-8279-395e14b8eb7d", "page": 10, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "ec1e27f3-11cc-42a8-8ff0-5e3493bf7129", "page": 10, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
{"id": "04cbec2e-4d69-4961-8d76-431729be6996", "page": 11, "type": "paragraph", "text": "n engl j med 389;24 nejm.org December 14, 2023"}
{"id": "aad0659a-3629-483d-9a92-fa638bb87983", "page": 11, "type": "paragraph", "text": "2255"}
{"id": "a649292a-86b6-4ff5-8fe8-8487731d2a16", "page": 11, "type": "paragraph", "text": "Recombinant or Standard-Dose Influenza Vaccine"}
{"id": "0bc3098d-8eeb-4deb-99e2-aaa9ed8f9951", "page": 11, "type": "paragraph", "text": "References"}
{"id": "6091dc8b-5c50-41f2-a202-d9d72936b05a", "page": 11, "type": "paragraph", "text": "1. Centers for Disease Control and Preven-"}
{"id": "5fc85ac5-9d91-4c57-bbb9-6b14001407de", "page": 11, "type": "paragraph", "text": "tion. Disease burden of flu (https://www\u200b"}
{"id": "6de577dc-342a-4b48-87f1-7077684d6090", "page": 11, "type": "paragraph", "text": ".\u00adcdc\u200b.\u00adgov/\u200b\u00adflu/\u200b\u00adabout/\u200b\u00adburden/\u200b\u00adindex\u200b.\u00adhtml)."}
{"id": "e401fa42-a239-43da-8f22-6a6694d10503", "page": 11, "type": "paragraph", "text": "2. Centers for Disease Control and Pre-"}
{"id": "824fe352-4a6b-41ec-bffe-b1a8bb525eb9", "page": 11, "type": "paragraph", "text": "vention. Seasonal flu vaccines (https://"}
{"id": "51e93623-6041-4e9c-9bde-9babb43156de", "page": 11, "type": "paragraph", "text": "www\u200b.\u00adcdc\u200b.\u00adgov/\u200b\u00adflu/\u200b\u00adprevent/\u200b\u00adflushot\u200b.\u00adhtm)."}
{"id": "faac05b9-f2dd-46f8-b10d-9e07f26a9d5c", "page": 11, "type": "paragraph", "text": "3. Centers for Disease Control and Pre-"}
{"id": "372017d0-d77f-446f-8f1c-e5e6b65b9f15", "page": 11, "type": "paragraph", "text": "vention. Vaccine effectiveness: how well"}
{"id": "f4857245-990b-48d0-a81a-e8df7b000dfe", "page": 11, "type": "paragraph", "text": "do flu vaccines work? (https://www\u200b.\u00adcdc\u200b"}
{"id": "c9d1fd3d-dcfa-48d7-9237-4eb5a4fddc94", "page": 11, "type": "paragraph", "text": ".\u00adgov/\u200b\u00adflu/\u200b\u00advaccines\u200b-\u00adwork/\u200b\u00advaccineeffect\u200b"}
{"id": "89769d2e-4896-4d23-bd62-fb9804b0cc93", "page": 11, "type": "paragraph", "text": ".\u00adhtm)."}
{"id": "a423a0bc-9858-42d0-8ea2-8dcb819e5ea9", "page": 11, "type": "paragraph", "text": "4. Wu NC, Lv H, Thompson AJ, et al. Pre-"}
{"id": "273011e7-0ef0-4e78-bf97-8e4e7b19c043", "page": 11, "type": "paragraph", "text": "venting an antigenically disruptive muta-"}
{"id": "477484bb-d8f4-442d-8222-9f6c7a8b2b20", "page": 11, "type": "paragraph", "text": "tion in egg-based H3N2 seasonal influen-"}
{"id": "53fc0645-7c43-4e09-8640-610c763bc545", "page": 11, "type": "paragraph", "text": "za vaccines by mutational incompatibility."}
{"id": "bed2ac26-8095-41f5-a484-fb51c55eb0e7", "page": 11, "type": "paragraph", "text": "Cell Host Microbe 2019;\u200b25(6):\u200b836.e5-844.e5."}
{"id": "c3e49002-bb83-4e61-bcde-9339c6c41cc8", "page": 11, "type": "paragraph", "text": "5. Dunkle LM, Izikson R, Patriarca P,"}
{"id": "1b67cf2f-3a3b-406e-85e4-18931b15b370", "page": 11, "type": "paragraph", "text": "et al. Efficacy of recombinant influenza"}
{"id": "5ba08c82-e1f1-495b-95de-0fb989f56538", "page": 11, "type": "paragraph", "text": "vaccine in adults 50 years of age or older."}
{"id": "f7e02d79-cbc9-40b2-b858-8928fe0acd30", "page": 11, "type": "paragraph", "text": "N Engl J Med 2017;\u200b376:\u200b2427-36."}
{"id": "3c7eb85e-4655-4518-a7f5-bdff796a74ca", "page": 11, "type": "paragraph", "text": "6. Krammer F. The human antibody re-"}
{"id": "7e6c9ac5-574a-4d49-85ca-0dcc89a38713", "page": 11, "type": "paragraph", "text": "sponse to influenza A virus infection and"}
{"id": "81d52d47-5599-48a1-a69e-704f9dad32fc", "page": 11, "type": "paragraph", "text": "vaccination. Nat Rev Immunol 2019;\u200b19:\u200b"}
{"id": "42976d0d-8541-4c08-8dc4-518d5050bbfd", "page": 11, "type": "paragraph", "text": "383-97."}
{"id": "32b140c1-a66a-4aa1-8a79-ccc7d04c700c", "page": 11, "type": "paragraph", "text": "7. Gordon NP. Similarity of adult Kaiser"}
{"id": "6d00df83-e567-482e-8d54-acf33b162dd9", "page": 11, "type": "paragraph", "text": "Permanente members to the adult popula-"}
{"id": "3c194608-861a-457d-849b-e1e573951866", "page": 11, "type": "paragraph", "text": "tion in Kaiser Permanente\u2019s northern Cali-"}
{"id": "9e3368e3-820f-41b1-9540-acdffb1a4bc8", "page": 11, "type": "paragraph", "text": "fornia service area: comparisons based on"}
{"id": "f7308ea1-8ed5-4548-978e-189698e01c23", "page": 11, "type": "paragraph", "text": "the 2017/2018 cycle of the California"}
{"id": "e83a5121-e30e-4597-a3f8-29ee203371c5", "page": 11, "type": "paragraph", "text": "Health Interview Survey, Oakland, CA:\u200b"}
{"id": "26bfd5c1-206c-4f3e-ac21-436e13288605", "page": 11, "type": "paragraph", "text": "Kaiser Permanente Northern California"}
{"id": "53afe316-c6de-42de-aab3-820d43f52889", "page": 11, "type": "paragraph", "text": "Division of Research, November 8, 2020"}
{"id": "c0423c29-e3ea-4de9-b08c-e8c572c7978b", "page": 11, "type": "paragraph", "text": "(https://memberhealthsurvey\u200b.\u00adkaiser\u200b.\u00adorg/\u200b"}
{"id": "55d2fd27-4247-4faf-8dab-5abdf44291ec", "page": 11, "type": "paragraph", "text": "\u00adresources/\u200b\u00adchis)."}
{"id": "7148b845-35a4-4f7c-9d3b-6496c7ce1d79", "page": 11, "type": "paragraph", "text": "8. Davis AC, Voelkel JL, Remmers CL,"}
{"id": "aadb456b-1c46-47d1-ba8a-a9a1b77f68b6", "page": 11, "type": "paragraph", "text": "Adams JL, McGlynn EA. Comparing Kai-"}
{"id": "afd34bbe-5271-4049-b780-4394960bdd66", "page": 11, "type": "paragraph", "text": "ser Permanente members to the general"}
{"id": "3a7af86a-9644-485f-8d49-d4e5b7ec2dd3", "page": 11, "type": "paragraph", "text": "population: implications for generalizabil-"}
{"id": "95fe04bb-f67d-4952-bf8b-fcec0883ade3", "page": 11, "type": "paragraph", "text": "ity of research. Perm J 2023;\u200b27:\u200b87-98."}
{"id": "c6c935f4-ad46-4da1-b327-1188e201afa8", "page": 11, "type": "paragraph", "text": "9. ClinicalTrials.gov. Flublok v. standard"}
{"id": "c5186201-6a94-4156-949d-2a2f1e03b12a", "page": 11, "type": "paragraph", "text": "dose vaccine effectiveness among Kaiser"}
{"id": "d4ed96d8-defd-40a5-bf80-307408f262ec", "page": 11, "type": "paragraph", "text": "Permanente Northern California adults"}
{"id": "a3e43371-a760-48e5-9228-9ab6b5115a42", "page": 11, "type": "paragraph", "text": "18-64 Years (https://clinicaltrials\u200b.\u00adgov/\u200b\u00adct2/\u200b"}
{"id": "91a779f6-e814-4c99-b340-f0bd4e1faceb", "page": 11, "type": "paragraph", "text": "\u00adshow/\u200b\u00adNCT03694392)."}
{"id": "7d966970-2c92-4ce5-aabc-3a778f2ba90d", "page": 11, "type": "paragraph", "text": "10. Food and Drug Administration. Mul-"}
{"id": "873c0bf6-ceb1-4f13-8fad-acff8546c910", "page": 11, "type": "paragraph", "text": "tiple endpoints in clinical trials: guidance"}
{"id": "e72c2852-4358-4052-9609-b30dbc65e183", "page": 11, "type": "paragraph", "text": "for industry. October 2022 (https://www\u200b"}
{"id": "418903b5-cc01-40e0-86f8-a41f089f6eb1", "page": 11, "type": "paragraph", "text": ".\u00adfda\u200b.\u00adgov/\u200b\u00adregulatory\u200b-\u00adinformation/\u200b\u00adsearch\u200b-\u00adfda\u200b"}
{"id": "12fa6062-1749-47d9-a17b-5c60cc2aef23", "page": 11, "type": "paragraph", "text": "-\u00adguidance\u200b-\u00addocuments/\u200b\u00admultiple\u200b-\u00adendpoints\u200b"}
{"id": "c4d1e48a-cff8-4ca1-923f-40ddf09cb3dc", "page": 11, "type": "paragraph", "text": "-\u00adclinical\u200b-\u00adtrials\u200b-\u00adguidance\u200b-\u00adindustry)."}
{"id": "b0b208b9-0122-4944-adcb-bc60143e3c4f", "page": 11, "type": "paragraph", "text": "11. Kochanek KD, Xu J, Arias E. Mortality"}
{"id": "fd4290c7-e0a7-42e1-840b-d18ea2a78c9e", "page": 11, "type": "paragraph", "text": "in the United States, 2019. NCHS Data"}
{"id": "593ea797-ea41-40ed-be7d-7453fcd22494", "page": 11, "type": "paragraph", "text": "Brief 2020;\u200b395:\u200b1-8."}
{"id": "89809f5d-cd29-4e75-a3d1-feb70093b466", "page": 11, "type": "paragraph", "text": "12. Sidney S, Sorel ME, Quesenberry CP,"}
{"id": "dfc465f3-ca30-4344-903b-23071e605fb6", "page": 11, "type": "paragraph", "text": "et al. Comparative trends in heart disease,"}
{"id": "1ee3c946-bab8-4dd2-bbf4-4d18b602ac35", "page": 11, "type": "paragraph", "text": "stroke, and all-cause mortality in the"}
{"id": "6a44ded1-eaa9-4741-9b7e-cfeb7f5410ee", "page": 11, "type": "paragraph", "text": "United States and a large integrated health-"}
{"id": "e65b2cd2-186b-4f9f-8893-46ed27f59716", "page": 11, "type": "paragraph", "text": "care delivery system. Am J Med 2018;\u200b131(7):\u200b"}
{"id": "524c7683-73e7-4859-86dd-2ba0efe0cf7f", "page": 11, "type": "paragraph", "text": "829.e1-836.e1."}
{"id": "ceb8ec3c-6105-4990-883f-a5bced2b13c7", "page": 11, "type": "paragraph", "text": "13. Centers for Disease Control and Preven-"}
{"id": "dcfb5cad-db29-4369-b015-834e550b1c5f", "page": 11, "type": "paragraph", "text": "tion. Past seasons\u2019 vaccine effectiveness es-"}
{"id": "1f94bf08-c4f9-4bff-a945-3db7d73f7201", "page": 11, "type": "paragraph", "text": "timates (https://www\u200b.\u00adcdc\u200b.\u00adgov/\u200b\u00adflu/\u200b\u00advaccines\u200b"}
{"id": "c16a885c-f6bf-4d61-80ac-ab1a0f0021a5", "page": 11, "type": "paragraph", "text": "-\u00adwork/\u200b\u00adpast\u200b-\u00adseasons\u200b-\u00adestimates\u200b.\u00adhtml)."}
{"id": "3a96f3a0-778f-42f4-a43b-f6480529e145", "page": 11, "type": "paragraph", "text": "14. Dunkle LM, Izikson R. Recombinant"}
{"id": "c370e0bb-b63b-4918-9e48-df9a812ee07b", "page": 11, "type": "paragraph", "text": "hemagglutinin influenza vaccine provides"}
{"id": "d5cc2b17-5de9-4106-be7f-63af4d2f54e6", "page": 11, "type": "paragraph", "text": "broader spectrum protection. Expert Rev"}
{"id": "41504e74-7a7c-48a9-8168-a2a41eecf2da", "page": 11, "type": "paragraph", "text": "Vaccines 2016;\u200b15:\u200b957-66."}
{"id": "abf1ca7e-7180-4a0d-a022-566deb7203ba", "page": 11, "type": "paragraph", "text": "15. Centers for Disease Control and Pre-"}
{"id": "91b7f0d9-a32b-44a3-932b-d605b8dbb2b0", "page": 11, "type": "paragraph", "text": "vention. ACIP flu meeting update: flu vac-"}
{"id": "f1e89a42-1dbd-40ec-984b-6cc84e64b3e7", "page": 11, "type": "paragraph", "text": "cines worked better than reported & ACIP"}
{"id": "3dc213c4-2bbc-4836-9906-8adef6d973f0", "page": 11, "type": "paragraph", "text": "recommends specific vaccines for seniors."}
{"id": "bd947e0f-2682-440a-95e4-15422cfb2d6c", "page": 11, "type": "paragraph", "text": "June 23, 2022 (https://www\u200b.\u00adcdc\u200b.\u00adgov/\u200b\u00adflu/\u200b"}
{"id": "5c7eaf9d-974e-4234-a87c-911f667aeee5", "page": 11, "type": "paragraph", "text": "\u00adspotlights/\u200b\u00ad2021\u200b-\u00ad2022/\u200b\u00adspecific\u200b-\u00advaccines\u200b"}
{"id": "431dd6b7-dff9-4865-845f-a73b7dc788e9", "page": 11, "type": "paragraph", "text": "-\u00adseniors\u200b.\u00adhtm)."}
{"id": "96b50e68-1a07-46eb-ab51-f1976d986ad0", "page": 11, "type": "paragraph", "text": "16. Grohskopf LA, Blanton LH, Ferdinands"}
{"id": "30b14e71-645f-423d-94e5-3388f329d7dc", "page": 11, "type": "paragraph", "text": "JM, et al. Prevention and control of sea-"}
{"id": "51861abc-2c2d-441f-98c2-f3671c61b239", "page": 11, "type": "paragraph", "text": "sonal influenza with vaccines: recom-"}
{"id": "a6ac5ef1-de26-4622-acb7-8ff7195982a8", "page": 11, "type": "paragraph", "text": "mendations of the Advisory Committee"}
{"id": "83eda7c9-391b-4bba-a3c8-d31a75945b39", "page": 11, "type": "paragraph", "text": "on Immunization Practices \u2014 United"}
{"id": "5dec4b7b-12d5-421b-978b-99c367754607", "page": 11, "type": "paragraph", "text": "States, 2022\u201323 influenza season. MMWR"}
{"id": "d7a844a9-f9a5-4728-b6bb-990b87a0edc9", "page": 11, "type": "paragraph", "text": "Recomm Rep 2022;\u200b71:\u200b1-28."}
{"id": "3e848bd1-10a0-468c-9d9e-c91b887484de", "page": 11, "type": "paragraph", "text": "17. Dawood FS, Naleway AL, Flannery B,"}
{"id": "2227b3be-e3d5-4b96-9092-434e3e338617", "page": 11, "type": "paragraph", "text": "et al. Comparison of the immunogenicity"}
{"id": "c894e905-e636-4242-ac90-706468dda6db", "page": 11, "type": "paragraph", "text": "of cell culture-based and recombinant"}
{"id": "1c5d9076-7249-48f4-ac90-e8286023b76e", "page": 11, "type": "paragraph", "text": "quadrivalent influenza vaccines to conven-"}
{"id": "763fcd7e-e1bc-4975-8572-3e8fcd0722a6", "page": 11, "type": "paragraph", "text": "tional egg-based quadrivalent influenza"}
{"id": "cdbafb2c-f26d-4544-8c8d-c7857cdee3e2", "page": 11, "type": "paragraph", "text": "vaccines among healthcare personnel aged"}
{"id": "98f933a8-193b-4afc-9982-f58eb936a853", "page": 11, "type": "paragraph", "text": "18-64 years: a randomized open-label trial."}
{"id": "ab07e9c6-7a5b-4b46-b4d8-300f032d32ba", "page": 11, "type": "paragraph", "text": "Clin Infect Dis 2021;\u200b73:\u200b1973-81."}
{"id": "f6578f51-0566-4894-a212-28281fab19eb", "page": 11, "type": "paragraph", "text": "18. California Department of Public"}
{"id": "cec1a509-6523-4a5e-bd23-69b407deb398", "page": 11, "type": "paragraph", "text": "Health. Influenza surveillance report,"}
{"id": "8491c631-d8c4-494d-a952-62e242eba237", "page": 11, "type": "paragraph", "text": "2018\u20132019 season. December 2019 (https://"}
{"id": "a4a6b573-81f6-4dfa-ae75-30eded2165c0", "page": 11, "type": "paragraph", "text": "www\u200b.\u00adcdph\u200b.\u00adca\u200b.\u00adgov/\u200b\u00adPrograms/\u200b\u00adCID/\u200b\u00adDCDC/\u200b"}
{"id": "89cf3bf1-b5bd-4ff4-b2bf-79baa577b2dd", "page": 11, "type": "paragraph", "text": "\u00adCDPH%20Document%20Library/\u200b"}
{"id": "c5d2c8d4-68b1-42e5-ae2f-5744115e97e3", "page": 11, "type": "paragraph", "text": "\u00adImmunization/\u200b\u00adAnnual2018\u200b-\u00ad19\u200b.\u00adpdf)."}
{"id": "6914c877-0802-4774-9a03-8b056a999f4a", "page": 11, "type": "paragraph", "text": "19. Flannery B, Kondor RJG, Chung JR,"}
{"id": "09f95a14-81e7-47d2-947b-c5d4ebd337f8", "page": 11, "type": "paragraph", "text": "et al. Spread of antigenically drifted influ-"}
{"id": "8c6be049-444c-4c1f-ad88-eda3e13a642e", "page": 11, "type": "paragraph", "text": "enza A(H3N2) viruses and vaccine effec-"}
{"id": "7dcb0f65-f925-47d2-8e44-5fa023dfabef", "page": 11, "type": "paragraph", "text": "tiveness in the United States during the"}
{"id": "d21aae49-04d9-4e01-bb17-406075858484", "page": 11, "type": "paragraph", "text": "2018-2019 season. J Infect Dis 2020;\u200b221:\u200b8-15."}
{"id": "58311541-f492-4398-a0e6-858a9e27c9ae", "page": 11, "type": "paragraph", "text": "20. Wang W, Alvarado-Facundo E, Vassell"}
{"id": "97a844ea-2e68-472d-8452-6fe888aad4ed", "page": 11, "type": "paragraph", "text": "R, et al. Comparison of A(H3N2) neutral-"}
{"id": "521feb4d-1166-423c-9839-5d7041c50136", "page": 11, "type": "paragraph", "text": "izing antibody responses elicited by 2018-"}
{"id": "9c006659-886a-40cd-a35b-db75c5990a88", "page": 11, "type": "paragraph", "text": "2019 season quadrivalent influenza vac-"}
{"id": "94c80e17-32dd-470c-ab29-1c9230d41b08", "page": 11, "type": "paragraph", "text": "cines derived from eggs, cells, and"}
{"id": "7f6222a1-8e09-4a0e-a213-7e5a2c7dc563", "page": 11, "type": "paragraph", "text": "recombinant hemagglutinin. Clin Infect"}
{"id": "71d97746-74c3-435c-8824-ad8ee8b93e6b", "page": 11, "type": "paragraph", "text": "Dis 2021;\u200b73(11):\u200be4312-e4320."}
{"id": "4be49264-45c7-4cce-9bc9-271c2291e6a1", "page": 11, "type": "paragraph", "text": "Copyright \u00a9 2023 Massachusetts Medical Society."}
{"id": "b021f810-0c13-4a53-9f52-9a7528a6b42f", "page": 11, "type": "paragraph", "text": "The New England Journal of Medicine"}
{"id": "21ed5453-4531-4863-94c6-bc80160aeb34", "page": 11, "type": "paragraph", "text": "Downloaded from nejm.org on August 22, 2024. For personal use only."}
{"id": "8920a826-19de-483c-807a-f91648bca4d2", "page": 11, "type": "paragraph", "text": "No other uses without permission. Copyright \u00a9 2023 Massachusetts Medical Society. All rights reserved."}
